<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">XXfCXQB8JXNY3jMH5xrH4Wy</article-id>
      <article-id pub-id-type="other">00004</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2009000800004</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(09)09300204</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2009000800004</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Preval&#234;ncia de s&#237;ndrome metab&#243;lica em idosos de uma comunidade: compara&#231;&#227;o entre tr&#234;s m&#233;todos diagn&#243;sticos</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Rigo</surname>
            <given-names>Julio Cesar</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vieira</surname>
            <given-names>Jos&#233; Luiz</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dalacorte</surname>
            <given-names>Roberta Rigo</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Reichert</surname>
            <given-names>C&#233;sar Luis</given-names>
          </name>
          <xref ref-type="aff" rid="aff03"/>
        </contrib>
      </contrib-group>
      <aff id="aff02">
        <addr-line>
          <named-content content-type="city">Porto Alegre</named-content>
          <named-content content-type="state">RS</named-content>
        </addr-line>
        <institution content-type="orgname">Funda&#231;&#227;o Universit&#225;ria de Cardiologia</institution>
        <institution content-type="orgdiv1">Instituto de Cardiologia do Rio Grande do Sul </institution>
      </aff>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="state">Rio Grande do Sul</named-content>
        </addr-line>
        <institution content-type="orgname">Pontif&#237;cia Universidade Cat&#243;lica do Rio Grande do Sul</institution>
        <institution content-type="orgdiv1">Instituto de Geriatria e Gerontologia </institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff03">
        <addr-line>
          <named-content content-type="city">Novo Hamburgo</named-content>
          <named-content content-type="state">RS</named-content>
        </addr-line>
        <institution content-type="orgname">Centro Universit&#225;rio Feevale</institution>
        <institution content-type="orgdiv1">Laborat&#243;rio de Fisiologia do Exerc&#237;cio </institution>
        <country country="BR">Brasil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>08</month>
        <year>2009</year>
      </pub-date>
      <volume>93</volume>
      <issue>2</issue>
      <fpage>85</fpage>
      <lpage>91</lpage>
      <history>
        <date date-type="accepted">
          <day>09</day>
          <month>10</month>
          <year>2008</year>
        </date>
        <date date-type="rev-recd">
          <day>29</day>
          <month>09</month>
          <year>2008</year>
        </date>
        <date date-type="received">
          <day>26</day>
          <month>05</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: A preval&#234;ncia de s&#237;ndrome metab&#243;lica (SM), encontrada em diferentes estudos, tem apresentado ampla varia&#231;&#227;o dependendo da popula&#231;&#227;o e do crit&#233;rio diagn&#243;stico utilizado, havendo uma tend&#234;ncia de maior preval&#234;ncia da SM com o crit&#233;rio diagn&#243;stico da International Diabetes Federation (IDF). OBJETIVO: Comparar a preval&#234;ncia da SM com diferentes crit&#233;rios em idosos de uma comunidade. M&#201;TODOS: Este &#233; um estudo transversal, de base populacional, realizado na cidade de Novo Hamburgo - RS, Brasil -, do qual participaram 378 idosos com 60 anos ou mais (252 mulheres e 126 homens). A preval&#234;ncia da SM foi estimada aplicando os crit&#233;rios diagn&#243;sticos do National Cholesterol Education Program - Adult Treatment Panel III (NCEP ATPIII) (2001), do NCEP ATPIII revisado (2005) e da IDF. RESULTADOS: A preval&#234;ncia de SM aumentou progressivamente com a utiliza&#231;&#227;o dos crit&#233;rios do NCEP ATP III, NCEP ATP III revisado e da IDF, apresentando valores de 50,3%, 53,4% e 56,9%, respectivamente. O aumento progressivo da preval&#234;ncia de SM com a utiliza&#231;&#227;o dos tr&#234;s crit&#233;rios ocorreu em ambos os sexos, com maior preval&#234;ncia entre as mulheres, com percentuais de 57,1%, 59,9% e 63,5% com os crit&#233;rios do NCEP ATP III, NCEP ATP III revisado e da IDF, respectivamente. CONCLUS&#195;O: Utilizando o crit&#233;rio da IDF, encontrou-se uma maior preval&#234;ncia de SM em rela&#231;&#227;o &#224; preval&#234;ncia encontrada com o crit&#233;rio do NCEP ATP III e NCEP ATP III revisado. A preval&#234;ncia da SM foi maior entre as mulheres, independente do crit&#233;rio utilizado.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Sindrome metab&#243;lica</kwd>
        <kwd>fatores de risco</kwd>
        <kwd>idoso</kwd>
        <kwd>preval&#234;ncia</kwd>
        <kwd>circunfer&#234;ncia abdominal</kwd>
        <kwd>press&#227;o arterial</kwd>
        <kwd>colesterol</kwd>
        <kwd>glicemia</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>13</day>
        <month>10</month>
        <year>2009</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>ARTIGO ORIGINAL </p>
    <p> CARDIOGERIATRIA</p>
    <p>Preval&#234;ncia de s&#237;ndrome metab&#243;lica em idosos de uma comunidade: compara&#231;&#227;o entre tr&#234;s m&#233;todos diagn&#243;sticos</p>
    <p>
      <bold>Julio Cesar Rigo<sup>I</sup>; Jos&#233; Luiz Vieira<sup>II</sup>; Roberta Rigo Dalacorte<sup>I</sup>; C&#233;sar Luis Reichert<sup>III</sup></bold>
    </p>
    <p><sup>I</sup>Instituto de Geriatria e Gerontologia da Pontif&#237;cia Universidade Cat&#243;lica do Rio Grande do Sul </p>
    <p><sup>II</sup>Funda&#231;&#227;o Universit&#225;ria de Cardiologia - Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre, RS </p>
    <p><sup>III</sup>Laborat&#243;rio de Fisiologia do Exerc&#237;cio do Centro Universit&#225;rio Feevale, Novo Hamburgo, RS - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="nt02">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> A preval&#234;ncia de s&#237;ndrome metab&#243;lica (SM), encontrada em diferentes estudos, tem apresentado ampla varia&#231;&#227;o dependendo da popula&#231;&#227;o e do crit&#233;rio diagn&#243;stico utilizado, havendo uma tend&#234;ncia de maior preval&#234;ncia da SM com o crit&#233;rio diagn&#243;stico da International Diabetes Federation (IDF). </p>
    <p><bold>OBJETIVO:</bold> Comparar a preval&#234;ncia da SM com diferentes crit&#233;rios em idosos de uma comunidade. </p>
    <p><bold>M&#201;TODOS:</bold> Este &#233; um estudo transversal, de base populacional, realizado na cidade de Novo Hamburgo - RS, Brasil -, do qual participaram 378 idosos com 60 anos ou mais (252 mulheres e 126 homens). A preval&#234;ncia da SM foi estimada aplicando os crit&#233;rios diagn&#243;sticos do National Cholesterol Education Program - Adult Treatment Panel III (NCEP ATPIII) (2001), do NCEP ATPIII revisado (2005) e da IDF. </p>
    <p><bold>RESULTADOS:</bold> A preval&#234;ncia de SM aumentou progressivamente com a utiliza&#231;&#227;o dos crit&#233;rios do NCEP ATP III, NCEP ATP III revisado e da IDF, apresentando valores de 50,3%, 53,4% e 56,9%, respectivamente. O aumento progressivo da preval&#234;ncia de SM com a utiliza&#231;&#227;o dos tr&#234;s crit&#233;rios ocorreu em ambos os sexos, com maior preval&#234;ncia entre as mulheres, com percentuais de 57,1%, 59,9% e 63,5% com os crit&#233;rios do NCEP ATP III, NCEP ATP III revisado e da IDF, respectivamente. </p>
    <p><bold>CONCLUS&#195;O:</bold> Utilizando o crit&#233;rio da IDF, encontrou-se uma maior preval&#234;ncia de SM em rela&#231;&#227;o &#224; preval&#234;ncia encontrada com o crit&#233;rio do NCEP ATP III e NCEP ATP III revisado. A preval&#234;ncia da SM foi maior entre as mulheres, independente do crit&#233;rio utilizado.</p>
    <p><bold>Palavras chave:</bold> Sindrome metab&#243;lica, fatores de risco, idoso, preval&#234;ncia, circunfer&#234;ncia abdominal, press&#227;o arterial, colesterol, glicemia.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>As doen&#231;as cardiovasculares representam, atualmente, a principal causa de morte no mundo. Sabe-se que o diabete melito (DM) est&#225; intimamente associado com o aumento do risco cardiovascular. A s&#237;ndrome metab&#243;lica (SM), caracterizada por obesidade central, dislipidemia, hiperglicemia e press&#227;o arterial lim&#237;trofe, &#233; hoje um dos maiores desafios para a sa&#250;de p&#250;blica em todo o mundo, por associar-se com um importante risco para doen&#231;a cardiovascular e diabete tipo 2. Como a SM se constitui em uma associa&#231;&#227;o de v&#225;rios fatores de risco cardiovascular, passou a representar um desafio na literatura<sup>1,2</sup> saber se o diagn&#243;stico da SM representa uma estimativa de risco cardiovascular maior que a associa&#231;&#227;o do risco individual de cada fator que a comp&#245;em. Diversos crit&#233;rios diagn&#243;sticos para a s&#237;ndrome metab&#243;lica surgiram na &#250;ltima d&#233;cada, tendo como objetivo uma identifica&#231;&#227;o precoce dos indiv&#237;duos sob elevado risco de desenvolver diabete e doen&#231;a cardiovascular<sup>3</sup>. Com o aumento da idade, existe um risco maior para a SM, devido &#224; tend&#234;ncia de maior preval&#234;ncia dos componentes da s&#237;ndrome entre os idosos<sup>4</sup>. </p>
    <p>A SM foi definida originalmente em 1998 pelo crit&#233;rio da Organiza&#231;&#227;o Mundial da Sa&#250;de (OMS), que apresentava como base eleva&#231;&#245;es da glicemia<sup>5</sup>. Dessa concep&#231;&#227;o glucoc&#234;ntrica de SM da OMS, evolu&#237;mos para o crit&#233;rio do <italic>National Cholesterol Education Program - Adult Treatment Panel III </italic>(NCEP ATPIII), formulado em 2001, onde a glicemia n&#227;o &#233; considerada um fator imprescind&#237;vel, passando a figurar somente como um dos componentes diagn&#243;sticos de SM<sup>6</sup>.</p>
    <p>Com a comprova&#231;&#227;o de evid&#234;ncias da rela&#231;&#227;o entre obesidade central e risco cardiovascular, ocorreu uma tend&#234;ncia de valorizar mais esse componente diagn&#243;stico para a SM. Assim, em 2004, a <italic>International Diabetes Federation</italic> (IDF) lan&#231;ou uma nova defini&#231;&#227;o de SM, onde a obesidade central, demarcada pelo valor da circunfer&#234;ncia abdominal, tornava-se imprescind&#237;vel para o diagn&#243;stico<sup>7,8</sup>. Com a ado&#231;&#227;o dessa defini&#231;&#227;o, foi observado uma maior preval&#234;ncia de SM na maioria das popula&#231;&#245;es estudadas, em especial entre os idosos<sup>9</sup>. Em 2005, em uma revis&#227;o dos crit&#233;rios de SM, a <italic>American Heart Association</italic> e o <italic>National Heart, Lung, and Blood Institute</italic> (AHA/NHLBI) mantiveram o crit&#233;rio do NCEP ATPIII. A justificativa foi o fato desse crit&#233;rio n&#227;o enfatizar uma &#250;nica etiologia para a SM e ser de maior simplicidade de aplica&#231;&#227;o, alterando apenas o ponto de corte da glicemia de jejum de 110 para 100 mg/dl, em decorr&#234;ncia de ajustes promovidos pela <italic>American Diabetes Association</italic> (ADA) no diagn&#243;stico de DM<sup>10</sup>. Contudo, a I Diretriz Brasileira de Diagn&#243;stico e Tratamento da SM, de 2005, utiliza, para o diagn&#243;stico, o crit&#233;rio do NCEP ATP III, de 2001<sup>11</sup>. </p>
    <p>No crit&#233;rio da IDF, o componente da circunfer&#234;ncia abdominal (CA) torna-se imprescind&#237;vel, estabelecendo valores mais rigorosos. Contudo, valores maiores de CA em idosos t&#234;m estado relacionados a menores valores de IMC, em rela&#231;&#227;o aos adultos jovens<sup>12</sup>.</p>
    <p>Os idosos s&#227;o o grupo da popula&#231;&#227;o com maior preval&#234;ncia de eventos cardiovasculares, logo, identificar a preval&#234;ncia de SM entre eles adquire grande import&#226;ncia para medidas de controle de risco. Al&#233;m disso, existe um maior risco para d&#233;ficits cognitivos entre os portadores da s&#237;ndrome, em especial quando a glicemia &#233; um dos componentes da SM<sup>13</sup>. Tamb&#233;m ocorre um risco duas vezes maior para a depress&#227;o entre mulheres com SM, conforme o crit&#233;rio do NCEP revisado<sup>14</sup>.A escassez de dados relativos &#224; nossa popula&#231;&#227;o quanto &#224; preval&#234;ncia da SM, em especial entre os idosos, contribui para justificar a import&#226;ncia deste estudo. </p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>Participaram do estudo, os idosos alocados na segunda etapa do "Estudo longitudinal sobre envelhecimento em Novo Hamburgo - RS, Brasil", com dados coletados de janeiro a julho de 2005. A primeira etapa do estudo havia sido realizada no ano de 2001, sendo composta por uma amostra probabil&#237;stica de 426 idosos. Na ocasi&#227;o, o tamanho amostral foi calculado em 376 indiv&#237;duos, para um intervalo de confian&#231;a de 95% e uma diferen&#231;a aceit&#225;vel m&#225;xima de 5%. Foi estimada uma preval&#234;ncia verdadeira de 50%, em uma popula&#231;&#227;o de 17.000 idosos, com controle para classe econ&#244;mica, sexo, idade e bairro de moradia. seguindo proporcionalidade pelos dados do IBGE - Censo 2000 -, de um total de 17.101 pessoas acima de 60 anos de idade, residentes no munic&#237;pio.</p>
    <p>Para a segunda etapa do estudo, no ano de 2005, houve a tentativa de contato por telefone ou carta com todos os participantes da primeira etapa. O processo de amostragem probabil&#237;stica utilizado nas duas fases do estudo (2001 e 2005) adotou os mesmos crit&#233;rios, sendo controlado para idade, sexo, local de moradia e classe econ&#244;mica, o que permitiu que as duas popula&#231;&#245;es fossem homog&#234;neas. Dos 426 idosos, 16 haviam falecido, segundo informa&#231;&#245;es de familiares, e 80 n&#227;o foram encontrados. Dos 330 pacientes restantes, 173 aceitaram participar, os que se recusaram foram substitu&#237;dos por outros, pelos mesmos crit&#233;rios da primeira fase. Ap&#243;s as reposi&#231;&#245;es, 379 idosos aceitaram participar do estudo (127 homens e 252 mulheres) assinando termo de consentimento informado. Para o presente estudo, foram inclu&#237;dos os 378 participantes que apresentavam os dados completos no banco de dados. O projeto foi aprovado pelo comit&#234; de &#233;tica do Hospital S&#227;o Lucas da Pontif&#237;cia Universidade Cat&#243;lica do Rio Grande do Sul, Brasil.</p>
    <p>Uma entrevista foi realizada, envolvendo a presen&#231;a de patologias pr&#233;vias e o uso de f&#225;rmacos, com avalia&#231;&#227;o metab&#243;lico-funcional no Centro Universit&#225;rio FEEVALE. A avalia&#231;&#227;o metab&#243;lico-funcional foi constitu&#237;da por medidas de peso, estatura, circunfer&#234;ncia da cintura e press&#227;o arterial, aferidas por pesquisadores treinados. O peso e a estatura foram avaliados em uma balan&#231;a antropom&#233;trica Welmy (Welmy<sup>&#174;</sup>, SP, Brasil). O IMC foi calculado a partir do peso em quilogramas dividido pelo quadrado da altura em metros. A circunfer&#234;ncia da cintura foi medida com fita m&#233;trica, no ponto m&#233;dio entre as &#250;ltimas costelas e as cristas il&#237;acas, no final do movimento respirat&#243;rio de expira&#231;&#227;o, em p&#233;. A press&#227;o arterial foi verificada duas vezes no bra&#231;o esquerdo, com o paciente sentado, ap&#243;s 10 minutos de descanso, com um esfigmoman&#244;metro aner&#243;ide previamente calibrado, sendo utilizada a m&#233;dia dos dois valores encontrados.</p>
    <p>As coletas de sangue foram realizadas com jejum de no m&#237;nimo 12 horas, sendo posteriormente analisadas no Laborat&#243;rio de Biomedicina do Centro Universit&#225;rio FEEVALE. Para a dosagem s&#233;rica da glicemia, do colesterol total, do HDL e dos triglicer&#237;deos (TG), foram usados kits da marca Labtest<sup>&#174;</sup>. As amostras foram analisadas por m&#233;todo enzim&#225;tico colorim&#233;trico em equipamento de semi-automa&#231;&#227;o. </p>
    <p>O diagn&#243;stico de SM foi definido para cada participante conforme os diferentes crit&#233;rios diagn&#243;sticos apresentados na <xref ref-type="table" rid="tab01">tabela 1</xref>. Quando o idoso estava em uso de medicamento anti-hipertensivo ou medicamento para controle de colesterol ou triglicer&#237;deos, o mesmo foi considerado positivo para a presen&#231;a daquele componente da SM, conforme defini&#231;&#245;es previamente estabelecidas pela IDF e NCEP ATPIII<sup>6,7,15</sup>. O ponto de corte utilizado para a CA no crit&#233;rio da IDF foi o da etnia europ&#233;ia, uma vez que a popula&#231;&#227;o era de descendentes de europeus. No crit&#233;rio do NCEP ATPIII revisado pela AHA/NHLBI, foi reduzido o ponto de corte da glicemia de jejum de 110 mg/dl para 100mg/dl<sup>10</sup>.</p>
    <table-wrap id="tab01">
      <graphic xlink:href="1678-4170-abc-93-02-0085-00004-gt01.jpg"/></table-wrap>
    <p>
      <bold>Procedimentos estat&#237;sticos </bold>
    </p>
    <p>Foi utilizado o pacote estat&#237;stico SPSS 13.0 (Chicago, IL) para a an&#225;lise dos dados. Os dados cont&#237;nuos foram apresentados como m&#233;dia &#177; desvio padr&#227;o ou mediana (AIQ: P25 a P75), e os categ&#243;ricos como n&#250;mero e porcentagem. Foram considerados significativos os testes que atingiram um erro alfa menor que 0,05 bicaudal. Para a an&#225;lise das preval&#234;ncias encontradas foi utilizado o teste Z para propor&#231;&#245;es e para a compara&#231;&#227;o entre as preval&#234;ncias de SM entre homens e mulheres foi utilizado o teste qui-quadrado.</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>Participaram do estudo 378 idosos, sendo 126 homens e 252 mulheres. As caracter&#237;sticas cl&#237;nicas da popula&#231;&#227;o estudada podem ser observadas na <xref ref-type="table" rid="tab02">tabela 2</xref>. As mulheres apresentaram um IMC maior e uma CA menor que a dos homens. J&#225; a press&#227;o arterial e a glicemia apresentaram valores similares entre os dois g&#234;neros. Em rela&#231;&#227;o ao perfil lip&#237;dico, o colesterol total, o LDL-colesterol e o HDL-colesterol foram maiores nas mulheres do que nos homens, e quanto aos n&#237;veis s&#233;ricos de triglicer&#237;deos foram encontrados valores medianos menores para os homens.</p>
    <table-wrap id="tab02">
      <graphic xlink:href="1678-4170-abc-93-02-0085-00004-gt02.jpg"/></table-wrap>
    <p>A preval&#234;ncia dos componentes dos diferentes crit&#233;rios de s&#237;ndrome metab&#243;lica est&#225; apresentada na <xref ref-type="fig" rid="a04fig01">figura 1</xref>. Em rela&#231;&#227;o aos componentes comuns aos tr&#234;s crit&#233;rios: a preval&#234;ncia do componente hipertens&#227;o entre todos os idosos participantes foi de 84%, sendo de 81% entre os homens e de 86% entre as mulheres; os n&#237;veis elevados de triglicer&#237;deos ou o uso de medica&#231;&#227;o espec&#237;fica para tratar hipertrigliceridemia estiveram presentes em 34% dos homens e 38% das mulheres; enquanto o HDL colesterol baixo esteve presente em 56% dos homens e em 72% das mulheres. A CA aumentada, pelos crit&#233;rios do NCEP/ATP III e NCEP/ATP III revisado, esteve presente em 29% dos homens e 56% das mulheres, enquanto que, pelo crit&#233;rio da IDF, esteve presente em 56% dos homens e 77% das mulheres. O componente glicemia <underline>&gt;</underline> 110 mg/dl ou diagn&#243;stico de diabete esteve presente em 14% dos homens e 17% das mulheres, j&#225; a presen&#231;a de glicemia <underline>&gt;</underline> 100 mg/dl ou diagn&#243;stico pr&#233;vio de diabete esteve presente em 27% dos homens e de 26% das mulheres.</p>
    <p content-type="asset">
      <fig id="a04fig01">
        <graphic xlink:href="1678-4170-abc-93-02-0085-00004-gf01.jpg"/></fig>
    </p>
    <p>A preval&#234;ncia de SM e as caracter&#237;sticas cl&#237;nicas dos participantes, com e sem esse diagn&#243;stico, segundo os diferentes crit&#233;rios est&#227;o apresentadas na <xref ref-type="table" rid="a04tab03">tabela 3</xref>. Foi observado um aumento progressivo da preval&#234;ncia de SM com a utiliza&#231;&#227;o dos crit&#233;rios NCEP ATP III, NCEP ATP III revisado e IDF, com valores de 50,3%, 53,4% e 56,9%, respectivamente. Quando comparamos as preval&#234;ncias de SM entre os tr&#234;s crit&#233;rios, por meio do teste Z para propor&#231;&#245;es, foi poss&#237;vel encontrar uma superioridade significativa somente entre o diagn&#243;stico da IDF em rela&#231;&#227;o ao NCEP ATP III (p = 0,0341). Contudo, n&#227;o foi encontrada diferen&#231;a significativa nas compara&#231;&#245;es de preval&#234;ncia entre o NCEP ATP III e o NCEP ATP III revisado (p= 0,1912), nem entre esse &#250;ltimo e a IDF (p=0,1708).</p>
    <p content-type="asset">
      <table-wrap id="a04tab03">
        <graphic xlink:href="1678-4170-abc-93-02-0085-00004-gt03.jpg"/></table-wrap>
    </p>
    <p>Tamb&#233;m foi poss&#237;vel observar que o IMC, independente do crit&#233;rio utilizado, foi em m&#233;dia 30 kg/m<sup>2</sup> para os idosos com SM e 25 kg/m<sup>2</sup> para aqueles sem SM. Em rela&#231;&#227;o aos diversos componentes da SM, tamb&#233;m ocorreram diferen&#231;as similares entre os idosos com e sem esse diagn&#243;stico, independente do crit&#233;rio aplicado. </p>
    <p>A <xref ref-type="table" rid="a04tab04">tabela 4</xref> apresenta a preval&#234;ncia da SM, conforme o g&#234;nero e as faixas et&#225;rias, de acordo com os tr&#234;s crit&#233;rios avaliados no estudo. O aumento progressivo da preval&#234;ncia de SM com a utiliza&#231;&#227;o dos crit&#233;rios NCEP ATP III, NCEP ATP III revisado e IDF ocorreu em ambos os sexos. Quando separados por g&#234;nero, foi observada uma maior preval&#234;ncia da SM entre as mulheres, com percentuais de 57,1%, 59,9% e 63,5%, respectivamente. Foi poss&#237;vel identificar na amostra estudada, um risco relativo para o diagn&#243;stico da SM em mulheres em rela&#231;&#227;o aos homens de 1,57 (intervalo de confian&#231;a IC 1,21 - 2,02) com o NCEP ATPIII, de 1,48 (IC 1,17 - 1,87) com o NCEP ATPIII revisado e de 1,45 (IC 1,17 - 1,81) com a IDF, todos com p &lt; 0,001. Entre os homens, a diferen&#231;a entre a preval&#234;ncia de SM pelos diferentes crit&#233;rios ocorreu somente na faixa et&#225;ria de 70 a 79 anos.</p>
    <p content-type="asset">
      <table-wrap id="a04tab04">
        <graphic xlink:href="1678-4170-abc-93-02-0085-00004-gt04.jpg"/></table-wrap>
    </p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>A preval&#234;ncia da SM nessa amostra representativa de idosos de uma comunidade foi considerada muito elevada. Al&#233;m disso, foi observado um aumento progressivo da preval&#234;ncia com a utiliza&#231;&#227;o dos crit&#233;rios do NCEP ATP III, do NCEP ATPIII revisado e da IDF, chegando a 43,3% entre os homens e 63,5% entre as mulheres, com esse &#250;ltimo crit&#233;rio.</p>
    <p>Na literatura, encontramos ampla varia&#231;&#227;o na preval&#234;ncia da SM em idosos, provavelmente por causa do perfil da popula&#231;&#227;o estudada e do crit&#233;rio empregado. A preval&#234;ncia variou de 11,3% nas mulheres e 12,5% nos homens com mais de 70 anos (utilizando o crit&#233;rio do NCEP ATPIII) em um estudo franc&#234;s representativo da popula&#231;&#227;o, para 69% em um estudo grego, tamb&#233;m de base populacional, entre idosos (com o crit&#233;rio da IDF<sup>16,17</sup>). </p>
    <p>Em um servi&#231;o de geriatria na Turquia, a preval&#234;ncia da SM entre os 1.255 indiv&#237;duos estudados, com 65 anos ou mais, foi de 24% com o crit&#233;rio do NCEP ATPIII<sup>18</sup>. Em um estudo colombiano na cidade de Bogot&#225;, que envolveu pacientes selecionados de uma cl&#237;nica de tratamento de hipertensos, com 40 anos ou mais, utilizando o crit&#233;rio do NCEP ATPIII, a preval&#234;ncia foi de 19% entre os homens e 30% entre as mulheres<sup>19</sup>. J&#225; na Cidade do Porto, em Portugal, entre uma amostra representativa dos adultos da cidade, a preval&#234;ncia da SM foi de 35% em homens e 33% em mulheres, tamb&#233;m pelo o crit&#233;rio do NCEP ATPIII<sup>20</sup>. Na It&#225;lia, em um estudo de corte de base populacional, representativo dos idosos com mais de 65 anos que vivem na comunidade, foi encontrada uma preval&#234;ncia de SM de 33% entre homens e 20% em mulheres, usando o crit&#233;rio do NCEP ATPIII<sup>21</sup>. </p>
    <p>Na popula&#231;&#227;o com mais de 60 anos da China, foi encontrada uma preval&#234;ncia elevada de SM (54% em mulheres e 35% em homens) pelo o crit&#233;rio da IDF, j&#225;, quando foi utilizado o crit&#233;rio do NCEP ATP III, a preval&#234;ncia caiu para 39% e 18%, respectivamente<sup>22</sup>. Entre australianos com mais de 70 anos, provenientes da comunidade de etnia europ&#233;ia, a preval&#234;ncia da SM pelo crit&#233;rio da IDF foi de 36% entre homens e 46% entre as mulheres<sup>9</sup>. J&#225; entre os italianos de Floren&#231;a com mais de 60 anos, foi observada uma maior preval&#234;ncia de SM no crit&#233;rio da IDF (52,8%) em rela&#231;&#227;o ao do NCEP revisado (3 63,1%)<sup>23</sup>.</p>
    <p>Um estudo longitudinal, com sete anos de acompanhamento, conduzido em Londrina-PR, avaliou a associa&#231;&#227;o de SM e obesidade abdominal com risco cardiovascular em mulheres idosas, pelo crit&#233;rio do NCEP ATP III. Das 516 idosas estudadas, com idade entre 0 e 84 anos, 206 (39,9%) tiveram o diagn&#243;stico de SM. No per&#237;odo, tamb&#233;m foram observados 94 (18,2%) eventos cardiovasculares (48 fatais e 46 n&#227;o-fatais). Ap&#243;s o ajuste para as vari&#225;veis confundidoras, a s&#237;ndrome metab&#243;lica e a raz&#227;o cintura-quadril acima do percentil 75 (&gt;0,98) foram preditores dos desfechos, com <italic>hazard ratio</italic> (HR) de 1,66 e 1,72, respectivamente. A CA aumentada (&gt;96 cm) n&#227;o foi um preditor estatisticamente significativo (HR 1,37, <italic>p </italic>= 0,12)<sup>24</sup>. </p>
    <p>Podemos observar, assim, uma ampla varia&#231;&#227;o da preval&#234;ncia da SM nos diferentes grupos populacionais, indicando a necessidade de estudos locais que definam essa preval&#234;ncia nas diferentes popula&#231;&#245;es e etnias. Quando comparado aos demais estudos de base populacional, o presente estudo observou uma elevada preval&#234;ncia de SM.</p>
    <p>Na literatura, encontramos uma tend&#234;ncia de aumento da preval&#234;ncia da SM quando &#233; utilizado o crit&#233;rio da IDF. Saber o impacto desse aumento de diagn&#243;sticos de SM na incid&#234;ncia de eventos coronarianos em idosos &#233; fundamental, por&#233;m, fora do objetivo deste estudo. Em um estudo de base populacional envolvendo adultos de 18 at&#233; 65 anos, foram comparados os crit&#233;rios diagn&#243;sticos da IDF e do NCEP ATPIII como preditores de desfechos cardiovasculares em 10 anos. Nesse estudo, de forma interessante, o crit&#233;rio do NCEP ATPIII teve maior valor preditivo para risco cardiovascular que o da IDF na popula&#231;&#227;o germ&#226;nica, embora mais casos de SM fossem diagnosticados pelo segundo crit&#233;rio<sup>25</sup>. Assim, ainda est&#225; para ser definido o crit&#233;rio diagn&#243;stico que permite melhor estimar o risco de eventos cardiovasculares em idosos.</p>
    <p>Foi observada em nossa amostra uma elevada preval&#234;ncia de press&#227;o arterial <underline>&gt;</underline> 130x85 mmHg, com 84% dos indiv&#237;duos apresentando esse componente diagn&#243;stico da SM. Apesar do ponto de corte baixo, sabemos que o risco para o desenvolvimento de complica&#231;&#245;es cardiovasculares varia com os valores de press&#227;o arterial, elevando-se a partir de valores acima de 110x75 mmHg<sup>26</sup>. O impacto isolado desse componente da SM no risco cardiovascular de idosos ainda deve ser mais bem definido. </p>
    <p>A eleva&#231;&#227;o dos TG tem estado associada de forma independente com o aumento de risco de eventos cardiovasculares<sup>27-29</sup>. No presente estudo, n&#237;veis de triglicer&#237;deos <underline>&gt;</underline> 150 mg/dl estiveram presentes em apenas 34% dos homens e 38% das mulheres, apesar do aparente perfil de risco elevado do grupo estudado.</p>
    <p>A preval&#234;ncia do fator CA teve grande varia&#231;&#227;o conforme o crit&#233;rio utilizado: NCEP ATP III, NCEP ATP III revisado ou IDF. Conforme o esperado, com o menor ponto de corte utilizado pela IDF, observa-se uma maior preval&#234;ncia desse componente quando &#233; utilizado esse crit&#233;rio. A obesidade central tem estado associada com o aumento de risco de morbimortalidade cardiovascular. Mesmo entre aqueles com peso dentro da faixa de normalidade, a adiposidade central pode elevar o risco de diabete, hipertens&#227;o, aterosclerose e, entre as mulheres, tamb&#233;m o de c&#226;ncer de mama. Al&#233;m disso, o aumento da circunfer&#234;ncia abdominal parece ser um bom preditor para o desenvolvimento de hipertens&#227;o e dislipidemia<sup>30</sup>, associando-se tamb&#233;m com o risco de infarto agudo do mioc&#225;rdio (IAM)<sup>31</sup>. A associa&#231;&#227;o entre o valor de CA e a gordura visceral deve ser caracterizada para cada popula&#231;&#227;o, com diferentes pontos de corte. Por exemplo: japoneses e indianos do sul da &#193;sia possuem maiores &#237;ndices de gordura total e visceral, o que leva a um risco maior de desenvolver diabete para um dado valor de IMC, em rela&#231;&#227;o aos europeus<sup>32</sup>. Estudos como esse indicaram a necessidade de utilizar pontos de corte diferentes de CA conforme cada grupo &#233;tnico, servindo como base te&#243;rica para o crit&#233;rio da IDF. Ainda n&#227;o h&#225; a defini&#231;&#227;o se esses pontos de corte mais r&#237;gidos predizem melhor a incid&#234;ncia de futuros eventos cardiovasculares, especialmente em idosos, uma vez que nessa popula&#231;&#227;o ocorrem maiores valores de CA associados com menores valores de IMC, em compara&#231;&#227;o ao adulto jovem. Esse achado pode estar relacionado com a tend&#234;ncia de maior ac&#250;mulo de gordura abdominal nos indiv&#237;duos idosos. Al&#233;m disso, entre os idosos, a CA e o IMC podem apresentar associa&#231;&#245;es inversas com mortalidade<sup>12</sup>. </p>
    <p>A CA na amostra estudada foi em m&#233;dia 12 cm maior entre os indiv&#237;duos com o diagn&#243;stico de SM pelos crit&#233;rios do NCEP ATP III e NCEP ATP III revisado, e de 14 cm pelo da IDF. Apesar dessas diferen&#231;as, os valores m&#233;dios da CA n&#227;o foram t&#227;o elevados, em ambos os sexos, o que certamente esteve associado com uma atenua&#231;&#227;o da preval&#234;ncia da SM, em especial pelo crit&#233;rio da IDF, embora a preval&#234;ncia encontrada tenha sido elevada. Isto ocorreu em decorr&#234;ncia principalmente da elevada frequ&#234;ncia dos outros componentes da SM.</p>
    <p>Por fim, a glicemia <underline>&gt;</underline> 110 mg/dl ou a presen&#231;a de Diabete apareceu em apenas 14% dos homens e 17% das mulheres no presente estudo. Quando foram utilizados os crit&#233;rios do NCEP ATP III revisado ou da IDF, ou seja, utilizando-se o ponto de corte mais rigoroso para a glicemia (<underline>&gt;</underline> 100 mg/dl), a preval&#234;ncia, conforme o esperado, elevou-se, chegando a 27% entre os homens e 26% entre as mulheres. Existem evid&#234;ncias de que a eleva&#231;&#227;o da glicose no soro est&#225; associada com o aumento do risco cardiovascular. Tamb&#233;m n&#227;o existem d&#250;vidas da rela&#231;&#227;o entre o diagn&#243;stico de diabete e a intoler&#226;ncia &#224; glicose com o processo ateroscler&#243;tico. No <italic>Nurses' Health Study</italic>, foi observado um aumento de risco para o IAM, anterior ao diagn&#243;stico de DM, de 3,17 vezes em um seguimento de 20 anos<sup>33</sup>. Uma meta-an&#225;lise demonstrou tamb&#233;m existir um aumento de risco cardiovascular associado com a presen&#231;a de intoler&#226;ncia &#224; glicose. Al&#233;m disso, quando comparados indiv&#237;duos com glicemia de jejum de 75 mg/dl com aqueles com 110mg/dl, foi observado um aumento de 33% no risco de evento cardiovascular<sup>34</sup>. Dessa forma, podemos evidenciar a import&#226;ncia de aumentos da glicose, mesmo em uma faixa previamente considerada normal, no risco cardiovascular.</p>
    <p>Ainda deve ser definido, com estudos de seguimento, se a maior preval&#234;ncia da SM encontrada no presente estudo, com o crit&#233;rio mais rigoroso da IDF, est&#225; realmente associada a uma maior previs&#227;o de eventos cardiovasculares do que o crit&#233;rio do NCEP ATPIII. </p>
    <p>No presente estudo, quando a amostra populacional dos idosos foi distribu&#237;da por faixas et&#225;rias e g&#234;neros, ocorreu uma perda de poder devido ao pequeno tamanho dos grupos, especialmente na faixa et&#225;ria acima de 80 anos, e, consequentemente, ocorreu uma perda na capacidade de generaliza&#231;&#227;o dos dados encontrados. </p>
    <p>
      <bold>Conclus&#227;o</bold>
    </p>
    <p>A preval&#234;ncia de s&#237;ndrome metab&#243;lica entre os idosos representativos da comunidade foi maior com o crit&#233;rio da IDF, seguido pelos crit&#233;rios do NCEP ATP III revisado e do NCEP ATP III. Al&#233;m disso, a preval&#234;ncia da s&#237;ndrome metab&#243;lica foi sempre maior entre as mulheres na amostra populacional estudada, independente do crit&#233;rio utilizado. </p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p> Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>Este artigo &#233; parte de disserta&#231;&#227;o de Mestrado de Julio Cesar Rigo pela Universidade Cat&#243;lica do Rio Grande do Sul.</p>
    <p>
      <fn id="nt02" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Julio C&#233;sar Rigo </p>
        <p> Rua Carazinho, 624/302 </p>
        <p> 90460-190 - Porto Alegre, RS - Brasil. </p>
        <p> Email: </p>
        <p>
          <email xlink:href="jcrigojc@gmail.com">jcrigojc@gmail.com</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 26/05/08; revisado recebido em 29/09/08 aceito em 09/10/08.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005; 28 (9): 2289-304.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes</article-title>
          <source>Diabetes Care</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>2289</fpage>
          <lpage>304</lpage>
          <issue>9</issue>
          <volume>28</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kahn</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Buse</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ferrannini</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Stern</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Bo S, Ciccone G, Baldi C, Be3nini L, Dusio F, Forastiere G, et al. Effectiveness of a lifestyle intervention on metabolic syndrome. A randomized controlled trial. J Gen Intern Med. 2007; 22 (12): 1695-703.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effectiveness of a lifestyle intervention on metabolic syndrome: A randomized controlled trial</article-title>
          <source>J Gen Intern Med</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>1695</fpage>
          <lpage>703</lpage>
          <issue>12</issue>
          <volume>22</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ciccone</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Baldi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Be3nini</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Dusio</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Forastiere</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Meigs JB. The metabolic syndrome. BMJ. 2003; 327 (7406): 61-2.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The metabolic syndrome</article-title>
          <source>BMJ</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>61</fpage>
          <lpage>2</lpage>
          <issue>7406</issue>
          <volume>327</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Meigs</surname>
              <given-names>JB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Dominguez LJ, Barbagallo M. The cardiometabolic syndrome and sarcopenic obesity in older persons. J Cardiometab Syndr. 2007; 2 (3): 183-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The cardiometabolic syndrome and sarcopenic obesity in older persons</article-title>
          <source>J Cardiometab Syndr</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>183</fpage>
          <lpage>9</lpage>
          <issue>3</issue>
          <volume>2</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Dominguez</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Barbagallo</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998; 15 (7): 539-53.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Definition, diagnosis and classification of diabetes mellitus and its complications: Part 1 diagnosis and classification of diabetes mellitus provisional report of a WHO consultation</article-title>
          <source>Diabet Med</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>539</fpage>
          <lpage>53</lpage>
          <issue>7</issue>
          <volume>15</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Alberti</surname>
              <given-names>KG</given-names>
            </name>
            <name>
              <surname>Zimmet</surname>
              <given-names>PZ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285 (19): 2486-97.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)</article-title>
          <source>JAMA</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>2486</fpage>
          <lpage>97</lpage>
          <issue>19</issue>
          <volume>285</volume>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome--a new worldwide definition. Lancet. 2005; 366: 1059-62.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The metabolic syndrome--a new worldwide definition</article-title>
          <source>Lancet</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1059</fpage>
          <lpage>62</lpage>
          <volume>366</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Alberti</surname>
              <given-names>KG</given-names>
            </name>
            <name>
              <surname>Zimmet</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. The IDF worldwide definition of the metabolic syndrome. 2006. [Acessed 2007 April 30]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.idf.org/home/index.cfm?node=1429">http://www.idf.org/home/index.cfm?node=1429</ext-link>.</mixed-citation>
        <element-citation publication-type="book">
          <source>The IDF worldwide definition of the metabolic syndrome</source>
          <date>
            <year>2006</year>
          </date>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Adams RJ, Appleton S, Wilson DH, Taylor AW, Dal Grande E, Chitleborough C, et al. Population comparison of two clinical approaches to the metabolic syndrome: implications of the new International Diabetes Federation consensus definition. Diabetes Care. 2005; 28 (11): 2777-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Population comparison of two clinical approaches to the metabolic syndrome: implications of the new International Diabetes Federation consensus definition</article-title>
          <source>Diabetes Care</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>2777</fpage>
          <lpage>9</lpage>
          <issue>11</issue>
          <volume>28</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Adams</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Appleton</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Dal Grande</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Chitleborough</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112 (17): 2735-52.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement</article-title>
          <source>Circulation</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>2735</fpage>
          <lpage>52</lpage>
          <issue>17</issue>
          <volume>112</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Grundy</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Cleeman</surname>
              <given-names>JI</given-names>
            </name>
            <name>
              <surname>Daniels</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Donato</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Eckel</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Franklin</surname>
              <given-names>BA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Sociedade Brasileira de Cardiologia. I Diretriz brasileira de diagn&#243;stico e tratamento da s&#237;ndrome metab&#243;lica. Arq Bras Cardiol. 2005; 84 (supl 1): 1-28.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>I Diretriz brasileira de diagn&#243;stico e tratamento da s&#237;ndrome metab&#243;lica</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1</fpage>
          <lpage>28</lpage>
          <volume>84</volume>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Woo J, Ho SC, Yu AL, Sham A. Is waist circumference a useful measure in predicting health outcomes in the elderly? Int J Obes Relat Metab Disord. 2002; 26 (10): 1349-55.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Is waist circumference a useful measure in predicting health outcomes in the elderly?</article-title>
          <source>Int J Obes Relat Metab Disord</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1349</fpage>
          <lpage>55</lpage>
          <issue>10</issue>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Woo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Sham</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Dik MG, Jonker C, Comijs HC, Kok A, Yaffe K, Penninx BW. Contribution of metabolic syndrome components to cognition in older individuals. Diabetes Care. 2007; 30 (10): 2655-60.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Contribution of metabolic syndrome components to cognition in older individuals</article-title>
          <source>Diabetes Care</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>2655</fpage>
          <lpage>60</lpage>
          <issue>10</issue>
          <volume>30</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Dik</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Jonker</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Comijs</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Kok</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yaffe</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Penninx</surname>
              <given-names>BW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Koponen H, Jokelainen J, Keinanen-Kiukaanniemi S, Kumpusalo E, Vanhala M. Metabolic syndrome predisposes to depressive symptoms: a population-based 7-year follow-up study. J Clin Psychiatry. 2008; 69 (2): 178-82.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Metabolic syndrome predisposes to depressive symptoms: a population-based 7-year follow-up study</article-title>
          <source>J Clin Psychiatry</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>178</fpage>
          <lpage>82</lpage>
          <issue>2</issue>
          <volume>69</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Koponen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Jokelainen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Keinanen-Kiukaanniemi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kumpusalo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Vanhala</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. The IDF consensus worldwide definition of the metabolic syndrome. 2005. [Accessed 2007 February 22]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.idf.org/webdata/docs/Metac_syndrome_def.pdf">http://www.idf.org/webdata/docs/Metac_syndrome_def.pdf</ext-link>.</mixed-citation>
        <element-citation publication-type="book">
          <source>The IDF consensus worldwide definition of the metabolic syndrome</source>
          <date>
            <year>2005</year>
          </date>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Guize L, Thomas F, Pannier B, Bean K, Danchin N, Benetos A. Metabolic syndrome: prevalence, risk factors and mortality in a French population of 62 000 subjects. Bull Acad Natl Med. 2006; 190 (3): 685-97.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Metabolic syndrome: prevalence, risk factors and mortality in a French population of 62 000 subjects</article-title>
          <source>Bull Acad Natl Med</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>685</fpage>
          <lpage>97</lpage>
          <issue>3</issue>
          <volume>190</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Guize</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Pannier</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Bean</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Danchin</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Benetos</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Athyros VG, Ganotakis ES, Elisaf M, Mikhailidis DP. The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin. 2005; 21 (8): 1157-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions</article-title>
          <source>Curr Med Res Opin</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1157</fpage>
          <lpage>9</lpage>
          <issue>8</issue>
          <volume>21</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Athyros</surname>
              <given-names>VG</given-names>
            </name>
            <name>
              <surname>Ganotakis</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Elisaf</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mikhailidis</surname>
              <given-names>DP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Cankurtaran M, Halil M, Yavuz BB, Dagli N, Oyan B, Ariogul S. Prevalence and correlates of metabolic syndrome (MS) in older adults. Arch Gerontol Geriatr. 2006; 42 (1): 35-45.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence and correlates of metabolic syndrome (MS) in older adults</article-title>
          <source>Arch Gerontol Geriatr</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>35</fpage>
          <lpage>45</lpage>
          <issue>1</issue>
          <volume>42</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cankurtaran</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Halil</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yavuz</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Dagli</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Oyan</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ariogul</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Lombo B, Villalobos C, Tique C, Satizabal C, Franco C. Prevalencia del sindrome metab&#243;lico entre los pacientes que asisten al servicio de clinica de hipertension de la Fundaci&#243;n Santa F&#233; de Bogot&#225;. Rev Col Cardiol. 2006; 12: 472-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalencia del sindrome metab&#243;lico entre los pacientes que asisten al servicio de clinica de hipertension de la Fundaci&#243;n Santa F&#233; de Bogot&#225;</article-title>
          <source>Rev Col Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>472</fpage>
          <lpage>8</lpage>
          <volume>12</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lombo</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Villalobos</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Tique</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Satizabal</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Franco</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Santos AC, Lopes C, Barros H. Prevalence of metabolic syndrome in the city of Porto. Rev Port Cardiol. 2004; 23 (1): 45-52.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence of metabolic syndrome in the city of Porto</article-title>
          <source>Rev Port Cardiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>45</fpage>
          <lpage>52</lpage>
          <issue>1</issue>
          <volume>23</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Santos</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Lopes</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Barros</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Ravaglia G, Forti P, Maioli F, Bastagli L, Chiappelli M, Montesi F, et al. Metabolic syndrome: prevalence and prediction of mortality in elderly individuals. Diabetes Care. 2006; 29 (11): 2471-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Metabolic syndrome: prevalence and prediction of mortality in elderly individuals</article-title>
          <source>Diabetes Care</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>2471</fpage>
          <lpage>6</lpage>
          <issue>11</issue>
          <volume>29</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ravaglia</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Forti</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Maioli</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bastagli</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Chiappelli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Montesi</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. He Y, Jiang B, Wang J, Feng K, Chang Q, Fan L, et al. Prevalence of the metabolic syndrome and its relation to cardiovascular disease in an elderly Chinese population. J Am Coll Cardiol. 2006; 47 (8): 1588-94.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence of the metabolic syndrome and its relation to cardiovascular disease in an elderly Chinese population</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>1588</fpage>
          <lpage>94</lpage>
          <issue>8</issue>
          <volume>47</volume>
          <person-group person-group-type="author">
            <name>
              <surname>He</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Feng</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Fan</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Mannucci E, Monami M, Bardini G, Ognibene A, Rotella CM. National Cholesterol Educational Program and International Diabetes Federation diagnostic criteria for metabolic syndrome in an Italian cohort: results from the FIBAR Study. J Endocrinol Invest. 2007; 30 (11): 925-30.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>National Cholesterol Educational Program and International Diabetes Federation diagnostic criteria for metabolic syndrome in an Italian cohort: results from the FIBAR Study</article-title>
          <source>J Endocrinol Invest</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>925</fpage>
          <lpage>30</lpage>
          <issue>11</issue>
          <volume>30</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mannucci</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Monami</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bardini</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ognibene</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rotella</surname>
              <given-names>CM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Cabrera MA, Gebara OC, Diament J, Nussbacher A, Rosano G, Wajngarten M. Metabolic syndrome, abdominal obesity, and cardiovascular risk in elderly women. Int J Cardiol. 2007; 114 (2): 224-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Metabolic syndrome, abdominal obesity, and cardiovascular risk in elderly women</article-title>
          <source>Int J Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>224</fpage>
          <lpage>9</lpage>
          <issue>2</issue>
          <volume>114</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cabrera</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Gebara</surname>
              <given-names>OC</given-names>
            </name>
            <name>
              <surname>Diament</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nussbacher</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rosano</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Wajngarten</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Assmann G, Guerra R, Fox G, Cullen P, Schulte H, Willett D, et al. Harmonizing the definition of the metabolic syndrome: comparison of the criteria of the adult treatment panel III and the International Diabetes Federation in United States American and European Populations. Am J Cardiol. 2007; 99 (4): 541-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Harmonizing the definition of the metabolic syndrome: comparison of the criteria of the adult treatment panel III and the International Diabetes Federation in United States American and European Populations</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>541</fpage>
          <lpage>8</lpage>
          <issue>4</issue>
          <volume>99</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Assmann</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Guerra</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fox</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cullen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Schulte</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Willett</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet. 2005; 365: 434-41.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk</article-title>
          <source>Lancet</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>434</fpage>
          <lpage>41</lpage>
          <volume>365</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Jackson</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lawes</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Bennett</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Milne</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Rodgers</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Tanne D, Koren-Morag N, Graff E, Goldbourt U. Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor. Circulation. 2001; 104 (24): 2892-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor</article-title>
          <source>Circulation</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>2892</fpage>
          <lpage>7</lpage>
          <issue>24</issue>
          <volume>104</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Tanne</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Koren-Morag</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Graff</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Goldbourt</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996; 3 (2): 213-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies</article-title>
          <source>J Cardiovasc Risk</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>213</fpage>
          <lpage>9</lpage>
          <issue>2</issue>
          <volume>3</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hokanson</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Austin</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29. Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J. 1998; 19 (Suppl A): A2-11.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The Munster Heart Study (PROCAM): Results of follow-up at 8 years</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>A2</fpage>
          <lpage>11</lpage>
          <volume>19</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Assmann</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cullen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Schulte</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30. Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr. 2004; 79 (3): 379-84.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Waist circumference and not body mass index explains obesity-related health risk</article-title>
          <source>Am J Clin Nutr</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>379</fpage>
          <lpage>84</lpage>
          <issue>3</issue>
          <volume>79</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Janssen</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Katzmarzyk</surname>
              <given-names>PT</given-names>
            </name>
            <name>
              <surname>Ross</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364: 937-52.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study</article-title>
          <source>Lancet</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>937</fpage>
          <lpage>52</lpage>
          <volume>364</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yusuf</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hawken</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ounpuu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dans</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Avezum</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lanas</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>32. Gallagher D, Heymsfield SB, Heo M, Jebb SA, Murgatroyd PR, Sakamoto Y. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am J Clin Nutr. 2000; 72 (3): 694-701.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index</article-title>
          <source>Am J Clin Nutr</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>694</fpage>
          <lpage>701</lpage>
          <issue>3</issue>
          <volume>72</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gallagher</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Heymsfield</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Heo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jebb</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Murgatroyd</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Sakamoto</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B33">
        <mixed-citation>33. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002; 25 (7): 1129-34.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes</article-title>
          <source>Diabetes Care</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1129</fpage>
          <lpage>34</lpage>
          <issue>7</issue>
          <volume>25</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hu</surname>
              <given-names>FB</given-names>
            </name>
            <name>
              <surname>Stampfer</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Haffner</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Solomon</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Willett</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Manson</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B34">
        <mixed-citation>34. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999; 22 (2): 233-40.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years</article-title>
          <source>Diabetes Care</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>233</fpage>
          <lpage>40</lpage>
          <issue>2</issue>
          <volume>22</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Coutinho</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gerstein</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yusuf</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Prevalence of metabolic syndrome in an elderly community: comparison between three diagnostic methods</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: The prevalence of the metabolic syndrome (MS) has shown wide variation in different studies, depending on the population sample and the diagnostic criteria used. The prevalence of MS tends to be higher with the diagnostic criteria of the International Diabetes Federation (IDF). OBJECTIVE: To compare the prevalence of MS using different criteria in an elderly community. METHODS: This was a cross-sectional population-based study conducted in the city of Novo Hamburgo - RS - Brazil, in which 378 elderly individuals, aged 60 years or over (252 women and 126 men) participated. The prevalence of MS was estimated using the National Cholesterol Education Program - Adult Treatment Panel III (NCEP ATPIII) (2001), the revised NCEP ATPIII (2005) and the IDF diagnostic criteria. RESULTS: The prevalence of MS increased progressively as we used the NCEP ATP III, the revised NCEP ATP III and the IDF criteria, with values of 50.3%, 53.4% and 56.9% respectively. The progressive increase in the prevalence of MS using the three criteria occurred in both genders, with a higher prevalence among women, with rates of 57.1%, 59.9% and 63.5% with the NCEP ATP III, the revised NCEP ATP III, and the IDF criteria, respectively. CONCLUSION: The use of the IDF criteria resulted in a higher prevalence of MS in comparison to the prevalence found with the NCEP ATP III criteria and the revised NCEP ATP III criteria. The prevalence of MS was higher among women, regardless of the criteria used.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Metabolic syndrome</kwd>
        <kwd>risk factors</kwd>
        <kwd>aged</kwd>
        <kwd>prevalence</kwd>
        <kwd>abdominal circumference</kwd>
        <kwd>blood pressure</kwd>
        <kwd>cholesterol</kwd>
        <kwd>blood glucose</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <p><undefined id="cima-body2"/>Prevalence of metabolic syndrome in an elderly community: comparison between three diagnostic methods </p>
      <p>
        <bold>Julio Cesar Rigo<sup>I</sup>; Jos&#233; Luiz Vieira<sup>II</sup>; Roberta Rigo Dalacorte<sup>I</sup>; C&#233;sar Luis Reichert<sup>III</sup></bold>
      </p>
      <p><sup>I</sup>Instituto de Geriatria e Gerontologia da Pontif&#237;cia Universidade Cat&#243;lica do Rio Grande do Sul, Porto Alegre, RS</p>
      <p><sup>II</sup>Funda&#231;&#227;o Universit&#225;ria de Cardiologia - Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre, RS</p>
      <p><sup>III</sup>Laborat&#243;rio de Fisiologia do Exerc&#237;cio do Centro Universit&#225;rio Feevale, Novo Hamburgo, RS - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>SUMMARY</bold>
      </p>
      <p><bold>BACKGROUND:</bold> The prevalence of the metabolic syndrome (MS) has shown wide variation in different studies, depending on the population sample and the diagnostic criteria used. The prevalence of MS tends to be higher with the diagnostic criteria of the International Diabetes Federation (IDF). </p>
      <p><bold>OBJECTIVE:</bold> To compare the prevalence of MS using different criteria in an elderly community.</p>
      <p><bold>METHODS:</bold> This was a cross-sectional population-based study conducted in the city of Novo Hamburgo - RS - Brazil, in which 378 elderly individuals, aged 60 years or over (252 women and 126 men) participated. The prevalence of MS was estimated using the National Cholesterol Education Program - Adult Treatment Panel III (NCEP ATPIII) (2001), the revised NCEP ATPIII (2005) and the IDF diagnostic criteria.</p>
      <p><bold>RESULTS:</bold> The prevalence of MS increased progressively as we used the NCEP ATP III, the revised NCEP ATP III and the IDF criteria, with values of 50.3%, 53.4% and 56.9% respectively. The progressive increase in the prevalence of MS using the three criteria occurred in both genders, with a higher prevalence among women, with rates of 57.1%, 59.9% and 63.5% with the NCEP ATP III, the revised NCEP ATP III, and the IDF criteria, respectively.</p>
      <p><bold>CONCLUSION:</bold> The use of the IDF criteria resulted in a higher prevalence of MS in comparison to the prevalence found with the NCEP ATP III criteria and the revised NCEP ATP III criteria. The prevalence of MS was higher among women, regardless of the criteria used.</p>
      <p><bold>Key words:</bold> Metabolic syndrome; risk factors; aged, prevalence; abdominal circumference; blood pressure; cholesterol; blood glucose.</p>
      <p>
        <bold>Introduction </bold>
      </p>
      <p>Cardiovascular diseases currently represent the main cause of death worldwide. It is well known that diabetes mellitus (DM) is closely associated with an increased cardiovascular risk. The metabolic syndrome (MS), characterized by central obesity, dyslipidemia, hyperglycemia and borderline blood pressure, is now one of the greatest challenges to public health throughout the world, due to its association with major risks for cardiovascular diseases and type 2 diabetes. As the MS is a combination of multiple cardiovascular risk factors, the challenge in literature is to find out if the diagnosis of MS entails greater potential cardiovascular risk than the combination of its individual risk factors<sup>1,2</sup>. Several diagnostic criteria for metabolic syndrome emerged in the last decade, aiming at the early identification of individuals at high risk of developing diabetes and cardiovascular diseases<sup>3</sup>. With older age, there is greater risk of MS, due to a tendency towards an increasing prevalence of the syndrome components among the elderly<sup>4</sup>. </p>
      <p>The MS was originally defined in 1998 by the criterion of the World Health Organization (WHO), which was based on the elevation of serum glucose levels<sup>5</sup>. From this glucose based concept of MS, used by the WHO, the definition evolved to the criteria of the National Cholesterol Education Program - Adult Treatment Panel III (NCEP ATPIII), issued in 2001, in which the glucose is not considered an essential factor, but only a diagnostic component of the MS<sup>6</sup>. </p>
      <p>When the relationship between central obesity and cardiovascular risk was confirmed, there was a tendency to give higher diagnostic value to that component of the MS. Therefore, in 2004, the International Diabetes Federation (IDF) issued a new definition of MS, in which central obesity, determined by the measurement of the waist circumference, was essential for the diagnosis<sup>7,8</sup>. Using this definition, a higher prevalence of MS was observed in most populations, especially among the elderly<sup>9</sup>. In 2005, a revision of the MS diagnostic criteria, conducted by the American Heart Association and the National Heart, Lung, and Blood Institute (AHA / NHLBI), maintained the NCEP ATPIII criteria, arguing that these criteria did not emphasize a single cause for MS and had easier application, only changing the cutoff point for fasting plasma glucose of 110 to 100 mg/dl, due to some adjustments that were determined by the American Diabetes Association (ADA) in the diagnosis of DM<sup>10</sup>. However, the I Brazilian Guidelines for Diagnosis and Treatment of MS-2005 still uses the NCEP ATP III diagnosis criteria of 2001<sup>11</sup>.</p>
      <p>By the IDF criteria, the abdominal circumference (AC) component is essential and has stricter values. However, in elderly patients, higher values of AC have been linked to lower values of BMI, when compared to what is observed in young adults<sup>12</sup>.</p>
      <p>The elderly are the population group with the highest prevalence of cardiovascular events. Therefore, determining the prevalence of MS among them is of great importance for establishing risk control measures. Moreover, there is greater risk for cognitive deficits among patients with MS, especially when blood glucose is a component of the MS<sup>13</sup>. There is also a two-fold higher risk for depression among women with MS, according to the revised NCEP criteria<sup>14</sup>. The scarcity of data on the prevalence of MS in our population, especially among the elderly, helps to justify the importance of this study. </p>
      <p>
        <bold>Methods </bold>
      </p>
      <p>Study participants were the elderly group allocated in the second stage of the "cross-sectional study on aging in Novo Hamburgo - RS - Brazil." Data were collected from January to July 2005. The first stage of the study was conducted in 2001, consisting of a random sample of 426 elderly patients: the sample size was estimated at 376 individuals for a confidence interval of 95% to a maximum acceptable difference of 5%, estimating a real prevalence of 50% in a population of 17,000 elderly individuals, with control adjustments for economic class, gender, age and area of residence, following the proportionality found in data from the IBGE 2000 Census, from a total of 17,101 city residents aged over 60 years. </p>
      <p>For the second stage of the study, in 2005, there was an attempt to contact all participants of the first stage by phone or letter. The process of probability sampling applied in the two phases of the study (2001 and 2005) used the same criteria, controlled for age, sex, place of residence and economic class, which allowed the two populations to be homogeneous. Of the 426 elderly individuals, 16 had died, according to information from relatives, and 80 were not found. Of the remaining 330, 173 agreed to participate, and those who replaced the missing individuals were selected by the same criteria used in the first phase. After the replacement, 379 seniors accepted to participate in the study (127 men and 252 women), signing an informed consent form. For this study, 378 participants who had complete data in the database were included. The project was approved by the ethics committee of the Hospital St. Luke of the Catholic University of Rio Grande do Sul, Brazil. </p>
      <p>An interview about the medical history of diseases and prior use of drugs, and a metabolic and functional assessment were conducted at the FEEVALE University Center. The metabolic-functional evaluation consisted of the measurement of weight, height, waist circumference and blood pressure by trained researchers. The weight and height were assessed on a Welmy anthropometrical scale (Welmy<sup>TM</sup> , Brazil). The BMI was calculated from weight in kilograms divided by the square of height in meters. The waist circumference was measured with tape, with the midpoint located between the last rib and the iliac crests, at the end of expiration, with the patient in a standing position. Blood pressure was measured twice in the left arm, with the patient in a sitting position, after 10 minutes of rest, with a previously calibrated aneroid sphygmomanometer, and the mean values were used. </p>
      <p>The blood samples were taken after a minimum of 12-hour fasting, and they were subsequently analyzed in the Laboratory of Biomedicine at the FEEVALE University Center. Serum glucose, total cholesterol, HDL and triglycerides levels were measured with Labtest &#174; kits. The samples were analyzed by the enzymatic colorimetric method in semi-automated equipment. </p>
      <p>The diagnosis of MS was determined for each participant according to the different diagnostic criteria presented in <xref ref-type="table" rid="tab1-body2">Table 1</xref>. When the elderly patient was using medications to control high blood pressure, cholesterol or triglycerides levels, the presence of that MS component was considered positive, as previously established by the IDF and the NCEP ATPIII definitions<sup>6,7,15</sup>. The cutoff point used for AC, by the IDF criteria, was the same used for the European ethnic group, because the population descended from Europeans. In the NCEP ATPIII criteria revised by the AHA/NHLBI the cutoff point for fasting plasma glucose was reduced from 110 mg/dL to 100mg/dL<sup>10</sup>.</p>
      <table-wrap id="tab1-body2">
        <graphic xlink:href="1678-4170-abc-93-02-0085-00004-gt01-en.jpg"/></table-wrap>
      <p>
        <bold>Statistical procedures </bold>
      </p>
      <p>We used the statistical program SPSS 13.0 (Chicago, IL) for data analysis. Continuous data were presented as mean &#177; standard deviation or median (AIQ: P25 to P75), and categorical data as number and percentage. The tests which resulted in an alpha error of less than 0.05, double-tailed, were considered significant. For the analysis of the observed prevalence, we used the Z test for proportions. To compare the MS prevalence among men and women, we used the chi-square test. </p>
      <p>
        <bold>Results </bold>
      </p>
      <p>Study participants were 378 elderly individuals, 126 men and 252 women. The clinical characteristics of the population are shown in <xref ref-type="table" rid="tab2-body2">Table 2</xref>. Women had lower BMI and WC values than men. Blood pressure and blood glucose showed similar values for both genders. Regarding the lipid profile, total cholesterol, LDL-cholesterol and HDL-cholesterol levels were higher in women than in men. Median values of serum triglycerides were lower among men. </p>
      <table-wrap id="tab2-body2">
        <graphic xlink:href="1678-4170-abc-93-02-0085-00004-gt02-en.jpg"/></table-wrap>
      <p>The prevalence of components according to different criteria for metabolic syndrome is shown in <xref ref-type="fig" rid="en_a04fig01-body2">Figure 1</xref>. For those components that are common to all three criteria, the prevalence of the component hypertension among all elderly participants was 84%, compared to 81% among men and 86% among women. High levels of triglycerides, or the use of specific medication to treat hypertriglyceridaemia, were present in 34% of men and 38% of women, whereas a low HDL cholesterol level was present in 56% of men and 72% of women. The increased AC, by the NCEP/ATP III and the revised NCEP/ATP III criteria, was present in 29% of men and 56% of women, whereas by the IDF criteria it was present in 56% of men and 77% of women. The component blood glucose <underline>&gt;</underline> 110 mg/dl or the diagnosis of diabetes was present in 14% of men and 17% of women, whereas the measurement of serum glucose <underline>&gt;</underline> 100 mg/dl or a previous diagnosis of diabetes was present in 27% of men and 26 % of women. </p>
      <p content-type="asset">
        <fig id="en_a04fig01-body2">
          <graphic xlink:href="1678-4170-abc-93-02-0085-00004-gf01-en.jpg"/></fig>
      </p>
      <p>The prevalence of MS and the clinical characteristics of participants with and without this diagnosis, according to different criteria, are presented in <xref ref-type="table" rid="en_a04tab03-body2">Table 3</xref>. We observed a progressive increase in the prevalence of MS using the NCEP ATP III, the revised NCEP ATP III and the IDF criteria, with values of 50.3%, 53.4% and 56.9%, respectively. When comparing the prevalence of MS among the three criteria using the Z test for proportions, we could only find a significant difference between the diagnosis by the IDF criteria and by the NCEP ATP III criteria (p = 0.0341). However no significant difference was found in a comparison of prevalence between the NCEP ATP III criteria and Revised NCEP ATP III criteria (p = 0.1912), or between the latter and the IDF criteria (p = 0.1708). </p>
      <p content-type="asset">
        <table-wrap id="en_a04tab03-body2">
          <graphic xlink:href="1678-4170-abc-93-02-0085-00004-gt03-en.jpg"/></table-wrap>
      </p>
      <p>It was observed that the BMI, regardless of the criteria used, was on average 30 kg/m<sup>2</sup> for the elderly with MS and 25 kg/m<sup>2</sup> for those without MS. In relation to the various components of MS, similar differences also occurred among the elderly with and without this diagnosis, independent of the criterion used. </p>
      <p><xref ref-type="table" rid="en_a04tab04-body2">Table 4</xref> shows the prevalence of MS, by gender and age groups, according to the three criteria evaluated in the study. The progressive increase in the prevalence of MS using the NCEP ATP III, the revised NCEP ATP III and the IDF criteria occurred in both genders. When separated by gender, there was a higher prevalence of MS among women, with rates of 57.1%, 59.9% and 63.5% respectively. In the sample, we identified a relative risk for the diagnosis of MS in women compared to men of 1.57 (confidence interval CI 1.21 to 2.02) with the NCEP ATPIII, of 1.48 (CI 1, 17 to 1.87) with the revised NCEP ATPIII, and of 1.45 (CI 1.17 to 1.81) with the IDF criteria, all of them with p &lt;0.001. Among men the difference between the prevalence of MS by the various criteria occurred only in the age group of 70 to 79 years. </p>
      <p content-type="asset">
        <table-wrap id="en_a04tab04-body2">
          <graphic xlink:href="1678-4170-abc-93-02-0085-00004-gt04-en.jpg"/></table-wrap>
      </p>
      <p>
        <bold>Discussion </bold>
      </p>
      <p>The prevalence of MS in this representative sample of elderly individuals in the community was very high. Moreover, there was a progressive increase in the prevalence using the criteria of the NCEP ATP III, the revised NCEP ATPIII and IDF, up to 43.3% among men and 63.5% among women with the latter criteria. </p>
      <p>In the literature, we found a wide variation in the prevalence of MS in the elderly, probably depending on the profile of the population and the criteria used, ranging from 11.3% in women and 12.5% in men aged over 70 years, using the NCEP ATP III criteria in a French representative study of the population, and up to 69% in a Greek study, also population-based, conducted among the elderly, using the IDF criteria<sup>16,17</sup>. </p>
      <p>In a geriatric service in Turkey, the prevalence of MS among the 1,255 subjects aged 65 years or over was 24% by the NCEP ATPIII criteria<sup>18</sup>. In a study conducted in the Colombian city of Bogota that involved patients selected from a treatment clinic of hypertensive patients, aged 40 or over, using the NCEP ATPIII criteria, the prevalence was 19% among men and 30% among women<sup>19</sup>. In the city of Oporto, Portugal, among a representative sample of adults in the city, the prevalence was 35% in men and 33% in women, also using the NCEP ATPIII criteria<sup>20</sup>. In Italy, a cohort population-based study conducted in a representative sample of elderly individuals aged over 65 years living in the community, found a prevalence of MS of 33% in men and 20% in women by the NCEP ATPIII criteria<sup>21</sup>. </p>
      <p>In the population aged over 60, in China, a high prevalence of MS (54% in women and 35% in men) was found using the IDF criteria, whereas by the NCEP ATP III criteria these rates were reduced to 39% and 18%, respectively<sup>22</sup>. Among a community group of Australians over 70 years, of European ethnicity, the prevalence of MS by the IDF criteria was 36% in men and 46% in women<sup>9</sup>. Among the Italians living in Florence, aged over 60 years, there was also a higher prevalence of MS by the IDF criteria (52.8%) in comparison to the revised NCEP criteria (33.1%)<sup>23</sup>. </p>
      <p>A cross-sectional study, with 7 years of monitoring, conducted in Londrina, Paran&#225;, assessed the association of MS by the NCEP ATP III criteria and abdominal obesity with cardiovascular risk in elderly women. Of the 516 elderly women included in the study, aged between 60 and 84 years, 206 (39.9%) had the diagnosis of MS. In the period, there were 94 (18.2%) cardiovascular events (48 fatal and 46 non-fatal). After adjusting for confounding variables, the metabolic syndrome and waist-hip ratio above the 75th percentile (&gt; 0.98) were predictors of outcomes, with hazard ratios (HR) of 1.66 and 1.72, respectively. The increased AC (&gt; 96 cm) was not a statistically significant predictor (HR 1.37, p = 0.12)<sup>24</sup>. </p>
      <p>We can see, therefore, a wide variation in the prevalence of MS in different populations, indicating the need for local studies to define the prevalence in different populations and ethnic groups. When compared to other population-based studies, in this study there was a high prevalence of MS.</p>
      <p>In the literature we found a trend of increasing prevalence of MS when using the IDF criteria. Determining the impact of an increase in diagnoses of MS on the incidence of coronary events in older people is fundamental, but this was not the objective of this study. In a population-based study involving adults aged 18 to 65 years, the IDF and the NCEP ATPIII diagnostic criteria were compared as predictors of cardiovascular outcomes in 10 years. In that study, it is interesting to note that the NCEP ATPIII criteria had a higher predictive value for cardiovascular risk than the IDF criteria in the German population, although more cases of MS were diagnosed by the latter criteria<sup>25</sup>. Therefore, which diagnostic criteria estimate better the risk of cardiovascular events in the elderly is yet to be defined. </p>
      <p>In our sample, we observed a high prevalence of blood pressure <underline>&gt;</underline> 130x85 mmHg, with 84% of individuals presenting this diagnostic component of MS. Despite the low cutoff point, we know that the risk of developing cardiovascular complications varies with the values of blood pressure, and the risk of these conditions increases as blood pressure rises above 110x75 mmHg<sup>26</sup>. The impact of this single component of MS on cardiovascular risk in the elderly should still be better defined. </p>
      <p>The elevation of TG has been independently associated with an increased risk of cardiovascular events<sup>27-29</sup>. In this study, triglyceride levels <underline>&gt;</underline> 150 mg/dl were present in only 34% of men and 38% of women, despite the apparent high risk profile of the study population. </p>
      <p>The prevalence of factor AC had great variations according to the criteria used: NCEP ATP III / revised NCEP ATP III or IDF. As expected, with the lower cutoff point used by the IDF there was a higher prevalence of this component when those criteria were used. Central obesity has been associated with an increased risk of cardiovascular morbidity and mortality. Even among those with normal weight, central adiposity may increase the risk of diabetes, hypertension, atherosclerosis and, among women, also of breast cancer. Furthermore, the increase in waist circumference seems to be a good predictor for the development of hypertension and dyslipidemia<sup> 30</sup>, and it is also associated with the risk of acute myocardial infarction<sup>31</sup>. The association between AC and the values of visceral fat should be characterized for each population, with different cutoff points. As an example, the Japanese and South Asian Indians have higher rates of total and visceral fat, which leads to greater risk of developing diabetes for a given value of BMI, in comparison to the Europeans<sup>32</sup>. Similar studies indicated the need to use different cut-off points for AC, according to each ethnic group, serving as a theoretical basis for the IDF criteria. It has not been clearly defined yet if these stricter cut-off points better predict the incidence of future cardiovascular events, especially in the elderly, as in this population higher values of AC are associated with lower values of BMI, in comparison to young adults. This finding may be related to the tendency of greater accumulation of abdominal fat in the elderly. Moreover, among the elderly, the AC and the BMI may have an inverse association with mortality<sup>12</sup>. </p>
      <p>In the sample, the AC was, on average, 12 cm larger among individuals with the diagnosis of MS by the NCEP ATP III / Revised NCEP ATP III criteria, and 14 cm, by the IDF criteria. Despite these differences, the average values of AC were not very high in both genders, which certainly was associated with a reduction in the prevalence of MS, particularly by the IDF criteria, although a high prevalence has been found. This high prevalence was mainly due to the high frequency of the other components of MS. </p>
      <p>Finally, blood glucose <underline>&gt;</underline> 110 mg/dl or diabetes was present in only 14% of men and 17% of women in this study. When using the revised NCEP ATP III or the IDF criteria, or using the stricter cut-off point for blood glucose (<underline>&gt;</underline> 100 mg/dl), the prevalence increased, as expected, reaching 27% among men and 26% among women. There are evidences that the elevation of serum glucose is associated with increased cardiovascular risk. There is also no doubt about the relationship between the diagnosis of diabetes and glucose intolerance with the atherosclerotic process. In the <italic>Nurses' Health Study</italic>, a 3.17 times increased risk of AMI was observed before the diagnosis of diabetes in a follow up of 20 years<sup>33</sup>. A meta-analysis also showed that there is an increased cardiovascular risk associated with the presence of glucose intolerance. Moreover, when comparing individuals who have fasting blood glucose of 75 mg/dl with those who have 110mg/dl, an increase of 33% in the risk of cardiovascular events was observed<sup>34</sup>. Therefore, we can highlight the importance of the glucose increases in the cardiovascular risk, even in a range previously considered normal. </p>
      <p>It is yet to be defined, with follow-up studies, if the higher prevalence of MS found in this study, using the stricter IDF criteria, is actually associated with a better prediction of cardiovascular events than when the NCEP ATPIII criteria are used. </p>
      <p>In this study, when the population of the elderly was distributed by age and gender, there was loss of power due to the small size of the groups, especially in the age group above 80 years, and, consequently, there was loss in the generalization ability of the compiled data.</p>
      <p>
        <bold>Conclusion </bold>
      </p>
      <p>The prevalence of the metabolic syndrome among the elderly was more representative in the community using the IDF criteria, followed by the revised NCEP ATP III criteria and NCEP ATP III criteria. Moreover, the prevalence of the metabolic syndrome was always higher among women in the studied population sample, regardless of the criteria used.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This article is part of the thesis of Master submitted by J&#250;lio C&#233;sar Rigo, from Universidade Cat&#243;lica do Rio Grande do Sul.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Prevalencia de s&#237;ndrome metab&#243;lico en adultos mayores: comparaci&#243;n entre tres m&#233;todos diagn&#243;sticos</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: prevalencia de s&#237;ndrome metab&#243;lico (SM), evidenciada en diferentes estudios, ha presentado amplia variaci&#243;n dependiendo de la poblaci&#243;n y del criterio diagn&#243;stico utilizado, habiendo una tendencia de mayor prevalencia del SM seg&#250;n el criterio diagn&#243;stico de la International Diabetes Federation (IDF). OBJETIVO: Comparar la prevalencia del SM con diferentes criterios en adultos mayores de una comunidad. M&#201;TODOS Este es un estudio transversal, de base poblacional, realizado en la ciudad de Novo Hamburgo - RS, Brasil -, del que participaron 378 adultos mayores con 60 a&#241;os o m&#225;s (252 mujeres y 126 varones). La prevalencia del SM se estim&#243; al aplicar los criterios diagn&#243;sticos del National Cholesterol Education Program - Adult Treatment Panel III (NCEP ATPIII) (2001), del NCEP ATPIII revisado (2005) y de la IDF. RESULTADOS: La prevalencia de SM aument&#243; progresivamente con la utilizaci&#243;n de los criterios del NCEP ATP III, NCEP ATP III revisado y de la IDF, presentando valores de un 50,3%, un 53,4% y el 56,9%, respectivamente. El aumento progresivo de la prevalencia de SM con la utilizaci&#243;n de los tres criterios ocurri&#243; en ambos los sexos, con mayor prevalencia entre las mujeres, con porcentajes de un 57,1%, un 59,9% y un 63,5% con los criterios del NCEP ATP III, NCEP ATP III revisado y de la IDF, respectivamente. CONCLUSI&#211;N: Al utilizar el criterio de la IDF, se pudo encontrar una mayor prevalencia de SM con relaci&#243;n a la prevalencia encontrada con el criterio del NCEP ATP III y NCEP ATP III revisado. La prevalencia de la SM fue mayor entre las mujeres, independientemente del criterio utilizado.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>S&#237;ndrome metab&#243;lico</kwd>
        <kwd>factores de riesgo</kwd>
        <kwd>adulto mayor</kwd>
        <kwd>prevalencia</kwd>
        <kwd>circunferencia abdominal</kwd>
        <kwd>presi&#243;n arterial</kwd>
        <kwd>colesterol</kwd>
        <kwd>glucemia</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p><undefined id="topo-body3"/>Prevalencia de s&#237;ndrome metab&#243;lico en adultos mayores. Comparaci&#243;n entre tres m&#233;todos diagn&#243;sticos</p>
      <p>
        <bold>Julio Cesar Rigo<sup>I</sup>; Jos&#233; Luiz Vieira<sup>II</sup>; Roberta Rigo Dalacorte<sup>I</sup>; C&#233;sar Luis Reichert<sup>III</sup></bold>
      </p>
      <p><sup>I</sup>Instituto de Geriatria e Gerontologia da Pontif&#237;cia Universidade Cat&#243;lica do Rio Grande do Sul, Porto Alegre, RS</p>
      <p><sup>II</sup>Funda&#231;&#227;o Universit&#225;ria de Cardiologia - Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre, RS</p>
      <p><sup>III</sup>Laborat&#243;rio de Fisiologia do Exerc&#237;cio do Centro Universit&#225;rio Feevale, Novo Hamburgo, RS - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO:</bold> prevalencia de s&#237;ndrome metab&#243;lico (SM), evidenciada en diferentes estudios, ha presentado amplia variaci&#243;n dependiendo de la poblaci&#243;n y del criterio diagn&#243;stico utilizado, habiendo una tendencia de mayor prevalencia del SM seg&#250;n el criterio diagn&#243;stico de la International Diabetes Federation (IDF).</p>
      <p><bold>OBJETIVO:</bold> Comparar la prevalencia del SM con diferentes criterios en adultos mayores de una comunidad.</p>
      <p><bold>M&#201;TODOS:</bold> Este es un estudio transversal, de base poblacional, realizado en la ciudad de Novo Hamburgo - RS, Brasil -, del que participaron 378 adultos mayores con 60 a&#241;os o m&#225;s (252 mujeres y 126 varones). La prevalencia del SM se estim&#243; al aplicar los criterios diagn&#243;sticos del <italic>National Cholesterol Education Program - Adult Treatment Panel III </italic>(NCEP ATPIII) (2001), del NCEP ATPIII revisado (2005) y de la IDF.</p>
      <p><bold>RESULTADOS:</bold> La prevalencia de SM aument&#243; progresivamente con la utilizaci&#243;n de los criterios del NCEP ATP III, NCEP ATP III revisado y de la IDF, presentando valores de un 50,3%, un 53,4% y el 56,9%, respectivamente. El aumento progresivo de la prevalencia de SM con la utilizaci&#243;n de los tres criterios ocurri&#243; en ambos los sexos, con mayor prevalencia entre las mujeres, con porcentajes de un 57,1%, un 59,9% y un 63,5% con los criterios del NCEP ATP III, NCEP ATP III revisado y de la IDF, respectivamente.</p>
      <p><bold>CONCLUSI&#211;N:</bold> Al utilizar el criterio de la IDF, se pudo encontrar una mayor prevalencia de SM con relaci&#243;n a la prevalencia encontrada con el criterio del NCEP ATP III y NCEP ATP III revisado. La prevalencia de la SM fue mayor entre las mujeres, independientemente del criterio utilizado. </p>
      <p><bold>Palabras clave:</bold> S&#237;ndrome metab&#243;lico, factores de riesgo, adulto mayor, prevalencia, circunferencia abdominal, presi&#243;n arterial, colesterol, glucemia.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>Las enfermedades cardiovasculares representan, actualmente, la principal causa de muerte en el mundo. Se sabe que el diabetes mellitus (DM) est&#225; &#237;ntimamente asociado al aumento del riesgo cardiovascular. El s&#237;ndrome metab&#243;lico (SM), caracterizado por obesidad central, dislipidemia, hiperglicemia y presi&#243;n arterial lim&#237;trofe, es hoy uno de los mayores retos para la salud p&#250;blica en todo el mundo, por asociarse a un importante riesgo para enfermedad cardiovascular y diabetes tipo 2. Como el SM est&#225; conformado por una asociaci&#243;n de diversos factores de riesgo cardiovascular, pas&#243; a representar un reto en la literatura<sup>1,2</sup> saber si el diagn&#243;stico del SM representa una estimaci&#243;n de riesgo cardiovascular mayor que la asociaci&#243;n del riesgo individual de cada factor que lo componen. Diversos criterios diagn&#243;sticos para el s&#237;ndrome metab&#243;lico han surgido en la &#250;ltima d&#233;cada, al tener como objetivo una identificaci&#243;n precoz de los individuos bajo elevado riesgo de desarrollar diabetes y enfermedad cardiovascular<sup>3</sup>. Con el avance de la edad, hay un riesgo mayor para el SM, debido a la tendencia de mayor prevalencia de los componentes del s&#237;ndrome entre los adultos mayores<sup>4</sup>. </p>
      <p>El SM se defini&#243; originalmente en 1998 por el criterio de la Organizaci&#243;n Mundial de Salud (OMS), que presentaba como base elevaciones de la glucemia<sup>5</sup>. Desde ese punto de vista glucoc&#233;ntrico del SM tomado por la OMS, evolucionamos al criterio del National Cholesterol Education Program - Adult Treatment Panel III (NCEP ATPIII), formulado en 2001, en el que no se considera la glucemia como un factor imprescindible, pasando a figurar solamente como uno de los componentes diagn&#243;sticos del SM<sup>6</sup>.</p>
      <p>Con la comprobaci&#243;n de evidencias de la relaci&#243;n entre obesidad central y riesgo cardiovascular, ocurri&#243; una tendencia de valorizar m&#225;s ese componente diagn&#243;stico para el SM. De ese modo, en el 2004, la International Diabetes Federation (IDF) lanz&#243; una nueva definici&#243;n de SM, en la que la obesidad central, demarcada por el valor de la circunferencia abdominal, se convert&#237;a en imprescindible para el diagn&#243;stico<sup>7,8</sup>. Con la adopci&#243;n de esa definici&#243;n, se observ&#243; una mayor prevalencia de SM en la mayor&#237;a de las poblaciones estudiadas, sobretodo entre los adultos mayores<sup>9</sup>. En el 2005, en una revisi&#243;n de los criterios de SM, la American Heart Association y el National Heart, Lung, and Blood Institute (AHA/NHLBI) mantuvieron en criterio del NCEP ATPIII. La justificaci&#243;n se ve evidenciada en el hecho de que ese criterio no enfatiza una &#250;nica etiolog&#237;a para el SM, adem&#225;s de ser de muy f&#225;cil de aplicaci&#243;n, al alterar solamente el punto de corte de la glucemia de ayuno de 110 para 100 mg/dL, en consecuencia de ayustes promovidos por la American Diabetes Association (ADA) en el diagn&#243;stico de DM<sup>10</sup>. Sin embargo, la I Directriz Brasile&#241;a de Diagn&#243;stico y Tratamiento del SM, del 2005, utiliza, para el diagn&#243;stico, el criterio del NCEP ATP III, del 2001<sup>11</sup>. </p>
      <p>En el criterio de la IDF, el componente de la circunferencia abdominal (CA) se vuelve imprescindible, al establecer valores m&#225;s rigurosos. No obstante, valores mayores de CA en adultos mayores han estado relacionados a menores valores de IMC, con relaci&#243;n a adultos j&#243;venes<sup>12</sup>.</p>
      <p>Los adultos mayores conforman el grupo de la poblaci&#243;n con mayor prevalencia de eventos cardiovasculares. Por lo tanto, la identificaci&#243;n de la prevalencia de SM entre ellos adquiere gran importancia para las mediciones de control de riesgo. Adem&#225;s de ello, existe un mayor riesgo para d&#233;ficits cognitivos entre los portadores del s&#237;ndrome, sobretodo cuando la glucemia es uno de los componentes del SM<sup>13</sup>. Tambi&#233;n ocurre un riesgo dos veces mayor para la depresi&#243;n entre mujeres con SM, seg&#250;n el criterio del NCEP revisado<sup>14</sup>. La escasez de datos relativos a nuestra poblaci&#243;n en cuanto a la prevalencia del SM, en especial entre los adultos mayores, contribuye a justificar la importancia de este estudio. </p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>Participaron en el estudio, los adultos mayores seleccionados en la segunda etapa del "Estudio longitudinal sobre envejecimiento en Novo Hamburgo - RS, Brasil", con datos recolectados de enero a julio de 2005. La primera etapa del estudio hab&#237;a sido realizada en el a&#241;o del 2001, siendo conformada por una muestra probabil&#237;stica de 426 adultos mayores. En la ocasi&#243;n, el tama&#241;o de la muestra se calcul&#243; en 376 individuos, para un intervalo de confianza del 95% y una diferencia aceptable m&#225;xima del 5%. Se estim&#243; una prevalencia verdadera del 50%, en una poblaci&#243;n de 17 mil adultos mayores, con control para clase econ&#243;mica, sexo, edad y barrio d&#243;nde viv&#237;an. Al seguir la proporcionalidad por los datos del IBGE (Instituto Brasile&#241;o de Geograf&#237;a y Estad&#237;stica) - Censo 2000 -, de un total de 17.101 personas con edad superior a 60 a&#241;os de edad, residentes en el municipio.</p>
      <p>Para la segunda etapa del estudio, en el a&#241;o de 2005, hubo la tentativa de contacto por tel&#233;fono o carta con todos los participantes de la primera etapa. El proceso de muestreo probabil&#237;stico utilizado en las dos fases del estudio (2001 y 2005) adopt&#243; los mismos criterios, siendo controlado para edad, sexo, local de habitaci&#243;n y clase econ&#243;mica, lo que permiti&#243; que las dos poblaciones fueran homog&#233;neas. De los 426 adultos mayores, 16 hab&#237;an fallecido, seg&#250;n informaciones de familiares, y a 80 no se encontraron. De los 330 pacientes remanentes, 173 aceptaron participar, los que se recusaron fueron sustituidos por otros, seg&#250;n los mismos criterios de la primera fase. Tras las sustituciones, 379 adultos mayores aceptaron participar en el estudio (127 varones y 252 mujeres) y firmaron el formulario de consentimiento informado. Para el presente estudio, se incluyeron a los 378 participantes que presentaban los datos completos en el banco de datos. El Comit&#233; de &#201;tica del Hospital S&#227;o Lucas de la Pontificia Universidad Cat&#243;lica del R&#237;o Grande del Sur, Brasil, aprob&#243; este proyecto.</p>
      <p>Una entrevista se llev&#243; a cabo, implicando la presencia de patolog&#237;as previas y el uso de f&#225;rmacos, con evaluaci&#243;n metab&#243;lico-funcional en el Centro Universitario FEEVALE. La evaluaci&#243;n metab&#243;lico-funcional estaba conformada por mediciones de peso, estatura, circunferencia de la cintura y presi&#243;n arterial, evaluadas por investigadores entrenados. El peso y la estatura se evaluaron en una balanza antropom&#233;trica Welmy (Welmy&#174;, SP, Brasil). El IMC se calcul&#243; a partir del peso en quilogramos dividido por el cuadrado de la altura en metros. La circunferencia de la cintura se midi&#243; con cinta m&#233;trica, en el punto medio entre las &#250;ltimas costillas y las crestas il&#237;acas, al final del movimiento respiratorio de espiraci&#243;n, de pi&#233;. Se verific&#243; la presi&#243;n arterial dos veces en el brazo izquierdo, con el paciente sentado, luego de 10 minutos de descanso, con un esfigmoman&#243;metro aneroide previamente calibrado, con la utilizaci&#243;n del promedio de los dos valores encontrados.</p>
      <p>Las extracciones de sangre se realizaron con ayuno de 12 horas, como m&#237;nimo, con an&#225;lisis posterior en el Laboratorio de Biomedicina del Centro Universitario FEEVALE. Para la dosificaci&#243;n s&#233;rica de la glucemia, del colesterol total, del HDL y de los triglic&#233;ridos (TG), se utilizaron kits de la marca Labtest<sup>&#174;</sup>. Las muestras se analizaron con m&#233;todo enzim&#225;tico colorim&#233;trico en equipo de semi automatizaci&#243;n. </p>
      <p>El diagn&#243;stico de SM se defini&#243; para cada participante seg&#250;n los diferentes criterios diagn&#243;sticos presentados en la <xref ref-type="table" rid="tab1-body3">Tabla 1</xref>. Cuando el adulto mayor estaba bajo tratamiento con el f&#225;rmaco antihipertensivo o medicaci&#243;n para control de colesterol o triglic&#233;ridos, el mismo se consider&#243; como positivo para la presencia de aquel componente del SM, conforme definiciones previamente establecidas por la IDF y NCEP ATPIII<sup>6,7,15</sup>. El punto de corte utilizado para la CA en el criterio de la IDF fue el de la etnia europea, una vez que la poblaci&#243;n era de descendientes de europeos. En el criterio del NCEP ATPIII revisado por la AHA/NHLBI, se reduzco el punto de corte de la glucemia de ayuno de 110 mg/dL para 100mg/dL<sup>10</sup>.</p>
      <table-wrap id="tab1-body3">
        <graphic xlink:href="1678-4170-abc-93-02-0085-00004-gt01-es.jpg"/></table-wrap>
      <p>
        <bold>Procedimientos estad&#237;sticos</bold>
      </p>
      <p>Se utiliz&#243; el paquete estad&#237;stico SPSS 13.0 (Chicago, IL) para el an&#225;lisis de los datos. Los datos continuos se presentaron como promedio &#177; desviaci&#243;n est&#225;ndar o mediana (AIQ: P25 a P75), y los categ&#243;ricos como n&#250;mero y porcentaje. Se consideraron como significativas las pruebas que alcanzaron un error alfa menor que 0.05 a dos colas. Para el an&#225;lisis de las prevalencias encontradas se utiliz&#243; la prueba Z para proporciones y para la comparaci&#243;n entre las prevalencias de SM entre varones y mujeres se utiliz&#243; la prueba Chi-cuadrado.</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>Participaron en el estudio 378 adultos mayores, siendo 126 varones y 252 mujeres. Las caracter&#237;sticas cl&#237;nicas de la poblaci&#243;n estudiada se pueden observar en la <xref ref-type="table" rid="tab2-body3">Tabla 2</xref>. Las mujeres presentaron un IMC mayor y una CA menor que la de los varones. Sin embargo, la presi&#243;n arterial y la glucemia presentaron valores similares entre los dos g&#233;neros. En cuanto al perfil lip&#237;dico, el colesterol total, el LDL-colesterol y el HDL-colesterol resultaron mayores en las mujeres que en los varones, y respecto a los niveles s&#233;ricos de triglic&#233;ridos se encontraron valores medianos menores para los varones.</p>
      <table-wrap id="tab2-body3">
        <graphic xlink:href="1678-4170-abc-93-02-0085-00004-gt02-es.jpg"/></table-wrap>
      <p>La prevalencia de los componentes de los diferentes criterios de s&#237;ndrome metab&#243;lico est&#225; presentada en la <xref ref-type="fig" rid="es_a04fig01-body3">Figura 1</xref>. Con relaci&#243;n a los componentes comunes a los tres criterios: la prevalencia del componente hipertensi&#243;n entre todos los adultos mayores participantes fue del 84%, siendo del 81% entre los varones y del 86% entre las mujeres. Los niveles elevados de triglic&#233;ridos o el uso de medicaci&#243;n espec&#237;fica para tratar la hipertrigliceridemia estuvieron presentes en el 34% de los varones y el 38% de las mujeres; mientras que el HDL colesterol bajo estuvo presente en el 56% de los varones y en el 72% de las mujeres. La CA aumentada, por los criterios del NCEP/ATP III y NCEP/ATP III revisado, estuvo presente en el 29% de los varones y el 56% de las mujeres, mientras que, por el criterio de la IDF, estuvo presente en el 56% de los hombres y el 77% de las mujeres. El componente glucemia <underline>&gt;</underline> 110 mg/dl &#243; diagn&#243;stico de diabetes estuvo presente en el 14% de los varones y el 17% de las mujeres. Sin embargo, la presencia de glucemia <underline>&gt;</underline> 100 mg/dL &#243; diagn&#243;stico previo de diabetes estuvo presente en el 27% de los varones y del 26% de las mujeres.</p>
      <p content-type="asset">
        <fig id="es_a04fig01-body3">
          <graphic xlink:href="1678-4170-abc-93-02-0085-00004-gf01-es.jpg"/></fig>
      </p>
      <p>La prevalencia de SM y las caracter&#237;sticas cl&#237;nicas de los participantes, con y sin ese diagn&#243;stico, seg&#250;n los diferentes criterios, est&#225;n presentadas en la <xref ref-type="table" rid="es_a04tab03-body3">Tabla 3</xref>. Se observ&#243; un aumento progresivo de la prevalencia de SM con la utilizaci&#243;n de los criterios NCEP ATP III, NCEP ATP III revisado e IDF, con valores de un 50,3%, un 53,4% y un 56,9%, respectivamente. Cuando comparamos las prevalencias de SM entre los tres criterios, por medio de la prueba Z para proporciones, fue posible encontrar una superioridad significativa solamente entre el diagn&#243;stico de la IDF con relaci&#243;n al NCEP ATP III (p = 0,0341). Sin embargo, no se evidenci&#243; diferencia significativa en las comparaciones de prevalencia entre el NCEP ATP III y el NCEP ATP III revisado (p= 0,1912), ni entre ese &#250;ltimo y la IDF (p=0,1708).</p>
      <p content-type="asset">
        <table-wrap id="es_a04tab03-body3">
          <graphic xlink:href="1678-4170-abc-93-02-0085-00004-gt03-es.jpg"/></table-wrap>
      </p>
      <p>Se pudo observar asimismo que el IMC, independientemente del criterio utilizado, tuvo un promedio 30 Kg/m2 para los adultos mayores con SM y 25 Kg/m2 para aquellos sin SM. En cuanto a los diversos componentes de la SM, tambi&#233;n ocurrieron diferencias similares entre los adultos mayores con y sin ese diagn&#243;stico, independientemente del criterio aplicado. </p>
      <p>La <xref ref-type="table" rid="es_a04tab04-body3">Tabla 4</xref> presenta la prevalencia del SM, seg&#250;n el g&#233;nero y los grupos de edad, de acuerdo con los tres criterios evaluados en el estudio. El aumento progresivo de la prevalencia de SM con la utilizaci&#243;n de los criterios NCEP ATP III, NCEP ATP III revisado e IDF ocurri&#243; en ambos los sexos. Cuando separados por g&#233;nero, se pudo observar una mayor prevalencia del SM entre las mujeres, con porcentajes de un 57,1%, un 59,9% y un 63,5%, respectivamente. Fue posible identificar en la muestra estudiada, un riesgo relativo para el diagn&#243;stico del SM en mujeres en cuanto a los varones de 1,57 (intervalo de confianza IC 1,21 - 2,02) con el NCEP ATPIII, de 1,48 (IC 1,17 - 1,87) con el NCEP ATPIII revisado y de 1,45 (IC 1,17 - 1,81) con la IDF, todos con p &lt; 0,001. Entre los varones, la diferencia entre la prevalencia de SM por los diferentes criterios ocurri&#243; solamente en el grupo de edad de 70 a 79 a&#241;os.</p>
      <p content-type="asset">
        <table-wrap id="es_a04tab04-body3">
          <graphic xlink:href="1678-4170-abc-93-02-0085-00004-gt04-es.jpg"/></table-wrap>
      </p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>La prevalencia del SM en esa muestra representativa de adultos mayores de una comunidad se revel&#243; muy elevada. Adem&#225;s, se observ&#243; un aumento progresivo de la prevalencia con la utilizaci&#243;n de los criterios del NCEP ATP III, del NCEP ATPIII revisado y de la IDF, llegando al 43,3% entre los varones y el 63,5% entre las mujeres, con ese &#250;ltimo criterio.</p>
      <p>En la literatura, encontramos una amplia variaci&#243;n en la prevalencia del SM en adultos mayores, probablemente por culpa del perfil de la poblaci&#243;n estudiada y del criterio empleado. La prevalencia vari&#243; del 11,3% en las mujeres y un 12,5% en los varones con m&#225;s de 70 a&#241;os (utilizando el criterio del NCEP ATPIII) en un estudio franc&#233;s representativo de la poblaci&#243;n, para el 69% en un estudio griego, tambi&#233;n de base poblacional, entre adultos mayores (con el criterio de la IDF<sup>16,17</sup>). </p>
      <p>En un servicio de geriatr&#237;a en Turqu&#237;a, la prevalencia del SM entre los 1.255 individuos estudiados, con 65 a&#241;os o m&#225;s, fue del 24% con el criterio del NCEP ATPIII<sup>18</sup>. En un estudio colombiano en la ciudad de Bogot&#225;, que implic&#243; a pacientes seleccionados de una cl&#237;nica de tratamiento de hipertensos, con 40 a&#241;os o m&#225;s, al utilizar el criterio del NCEP ATPIII, la prevalencia fue del 19% entre los varones y del 30% entre las mujeres<sup>19</sup>. Sin embargo, en la ciudad de Porto, en Portugal, entre una muestra representativa de los adultos de la regi&#243;n, la prevalencia del SM fue del 35% en varones y del 33% en mujeres, tambi&#233;n debido al criterio del NCEP ATPIII<sup>20</sup>. En Italia, en un estudio de corte de base poblacional, representativo de los adultos mayores con m&#225;s de 65 a&#241;os que viven en la comunidad, se evidenci&#243; una prevalencia de SM del 33% entre varones y el 20% en mujeres, al usar el criterio del NCEP ATPIII<sup>21</sup>. </p>
      <p>En la poblaci&#243;n con m&#225;s de 60 a&#241;os de China, se revel&#243; una prevalencia elevada de SM (un 54% en mujeres y un 35% en varones) seg&#250;n el criterio de la IDF. Sin embargo, cuando se utiliz&#243; el criterio del NCEP ATP III, la prevalencia baj&#243; para el 39% y el 18%, respectivamente<sup>22</sup>. Entre australianos con m&#225;s de 70 a&#241;os, provenientes de la comunidad de etnia europea, la prevalencia del SM seg&#250;n el criterio de la IDF fue del 36% entre varones y 46% entre las mujeres<sup>9</sup>. No obstante, entre los italianos de Florencia con m&#225;s de 60 a&#241;os, se observ&#243; una mayor prevalencia de SM en el criterio de la IDF (52,8%) con relaci&#243;n al del NCEP revisado (33,1%)<sup>23</sup>.</p>
      <p>Un estudio longitudinal, con siete a&#241;os de seguimiento, conducido en Londrina-PR, Brasil, evalu&#243; la asociaci&#243;n de SM y obesidad abdominal con riesgo cardiovascular en mujeres adultas mayores, seg&#250;n el criterio del NCEP ATP III. De las 516 adultas mayores estudiadas, con edad entre 60 y 84 a&#241;os, 206 (39,9%) tuvieron el diagn&#243;stico de SM. En el per&#237;odo, tambi&#233;n se observaron 94 (18,2%) eventos cardiovasculares (48 fatales y 46 no-fatales). Tras el ajuste para las variables confundidoras, el s&#237;ndrome metab&#243;lico y la raz&#243;n cintura-cadera superior al percentil 75 (&gt;0,98) fueron predictores de los desenlaces, con hazard ratio (HR) de 1,66 y 1,72, respectivamente. La CA aumentada (&gt;96 cm) no fue un predictor estad&#237;sticamente significativo (HR 1,37, p = 0,12)<sup>24</sup>. </p>
      <p>Podemos observar, as&#237;, una amplia variaci&#243;n de la prevalencia del SM en los diferentes grupos poblacionales, indicando la necesidad de estudios locales que definan esa prevalencia en las diferentes poblaciones y etnias. Cuando comparado a los dem&#225;s estudios de base poblacional, el presente estudio observ&#243; una elevada prevalencia de SM.</p>
      <p>En la literatura, encontramos una tendencia de aumento de la prevalencia del SM cuando se utiliza el criterio de la IDF. Saber el impacto de ese aumento de diagn&#243;sticos de SM en la incidencia de eventos coronarios en adultos mayores es fundamental, aunque est&#225; fuera del objetivo de este estudio. En un estudio de base poblacional que incluy&#243; a adultos desde 18 hasta 65 a&#241;os, se compararon los criterios diagn&#243;sticos de la IDF y del NCEP ATPIII como predictores de desenlaces cardiovasculares en 10 a&#241;os. En ese estudio, de forma interesante, el criterio del NCEP ATPIII tuvo mayor valor predictivo para riesgo cardiovascular que el de la IDF en la poblaci&#243;n germ&#225;nica, aunque m&#225;s casos de SM se diagnosticaban por el segundo criterio<sup>25</sup>. De esa forma, est&#225; a&#250;n para definirse el criterio diagn&#243;stico que permite mejor estimar el riesgo de eventos cardiovasculares en adultos mayores.</p>
      <p>Se observ&#243; en nuestra muestra elevada prevalencia de presi&#243;n arterial <underline>&gt;</underline>130/85 mmHg, con el 84% de los individuos presentando ese componente diagn&#243;stico del SM. A pesar del bajo punto de corte, sabemos que el riesgo para el desarrollo de complicaciones cardiovasculares var&#237;a de acuerdo a los valores de presi&#243;n arterial, elevando a partir de valores arriba de 110/75 mmHg<sup>26</sup>. El impacto aislado de ese componente del SM en el riesgo cardiovascular de adultos mayores debe ser todav&#237;a m&#225;s bien definido. </p>
      <p>La elevaci&#243;n de los TG ha estado asociada de forma independiente al aumento de riesgo de eventos cardiovasculares<sup>27-29</sup>. En el presente estudio, niveles de triglic&#233;ridos <underline>&gt;</underline> 150 mg/dl estuvieron presentes en solamente el 34% de los varones y el 38% de las mujeres, pese el aparente perfil de riesgo elevado del grupo estudiado.</p>
      <p>La prevalencia del factor CA tuvo una gran variaci&#243;n seg&#250;n el criterio utilizado: NCEP ATP III, NCEP ATP III revisado o IDF. Como se esperaba, con menor punto de corte utilizado por la IDF, se observa una mayor prevalencia de ese componente cuando se utiliza ese criterio. La obesidad central ha estado asociada al aumento de riesgo de morbimortalidad cardiovascular. Incluso entre aquellos con peso dentro del grupo de normalidad, la adiposidad central puede elevar el riesgo de diabetes, hipertensi&#243;n, aterosclerosis y, entre las mujeres, tambi&#233;n el de c&#225;ncer de mama. Adem&#225;s, el aumento de la circunferencia abdominal parece ser un buen predictor para el desarrollo de hipertensi&#243;n y dislipidemia<sup>30</sup>, asoci&#225;ndose tambi&#233;n al riesgo de infarto agudo de miocardio (IAM)<sup>31</sup>. La asociaci&#243;n entre el valor de CA y la grasa visceral se debe caracterizar para cada poblaci&#243;n, con diferentes puntos de corte. Por ejemplo: japoneses e indios del sur de Asia tienen mayores &#237;ndices de grasa total y visceral, lo que conlleva un riesgo mayor de desarrollar diabetes para un cierto valor de IMC, con relaci&#243;n a los europeos<sup>32</sup>. Estudios como ese indicaron la necesidad de utilizar puntos de corte diferentes de CA seg&#250;n cada grupo &#233;tnico, sirviendo como base te&#243;rica para el criterio de la IDF. Todav&#237;a no hay definici&#243;n si esos puntos de corte m&#225;s r&#237;gidos predicen mejor incidencia de futuros eventos cardiovasculares, sobretodo en adultos mayores, una vez que en esa poblaci&#243;n ocurren mayores valores de CA asociados con menores valores de IMC, en comparaci&#243;n al adulto joven. Ese hallazgo puede estar relacionado a la tendencia de mayor acumulo de grasa abdominal en los individuos adultos mayores. Adem&#225;s, entre los adultos mayores, la CA y el IMC pueden presentar asociaciones inversas con mortalidad<sup>12</sup>. </p>
      <p>La CA en la muestra estudiada fue en un promedio 12 cm mayor entre los individuos con el diagn&#243;stico de SM seg&#250;n los criterios del NCEP ATP III y NCEP ATP III revisado, y de 14 cm seg&#250;n los de la IDF. Pese a esas diferencias, los valores promedios de la CA no resultaron tan elevados, en ambos sexos, lo que ciertamente estuvo asociado a una atenuaci&#243;n de la prevalencia del SM, en especial seg&#250;n el criterio de la IDF, aunque la prevalencia encontrada es elevada. Esto ocurri&#243; en consecuencia principalmente de la elevada frecuencia de los otros componentes del SM.</p>
      <p>Por fin, la glucemia <underline>&gt;</underline> 110 mg/dL o la presencia de diabetes se evidenci&#243; en solamente el 14% de los varones y el 17% de las mujeres en el presente estudio. Cuando se utilizaron los criterios del NCEP ATP III revisado o de la IDF, es decir, al utilizar el punto de corte m&#225;s riguroso para la glucemia (<underline>&gt;</underline> 100 mg/dL), la prevalencia, de acuerdo con lo que se esperaba, se elev&#243;, llegando a un 27% entre los varones y un 26% entre las mujeres. Hay evidencias de que la elevaci&#243;n de la glucosa en el suero est&#225; asociada con el aumento del riesgo cardiovascular. Tambi&#233;n no hay dudas de la relaci&#243;n entre el diagn&#243;stico de diabetes y la intolerancia a la glucosa con el proceso ateroscler&#243;tico. En el Nurses' Health Study, se observ&#243; un aumento de riesgo para el IAM, anterior al diagn&#243;stico de DM, de 3,17 veces en un seguimiento de 20 a&#241;os<sup>33</sup>. Un meta-an&#225;lisis evidenci&#243; que tambi&#233;n hay un aumento de riesgo cardiovascular asociado con la presencia de intolerancia a la glucosa. Adem&#225;s, cuando comparados individuos con glucemia de ayuno de 75 mg/dL con aquellos con 110mg/dL, se observ&#243; un aumento del 33% en el riesgo de evento cardiovascular<sup>34</sup>. De esa forma, podemos evidenciar la importancia de aumentos de la glucosa, incluso en un grupo previamente considerado normal, en el riesgo cardiovascular.</p>
      <p>Todav&#237;a se debe definir, con estudios de seguimiento, si la mayor prevalencia del SM encontrada en el presente estudio, con el criterio m&#225;s riguroso de la IDF, est&#225; realmente asociada a una mayor previsi&#243;n de eventos cardiovasculares que el criterio del NCEP ATPIII. </p>
      <p>En el presente estudio, cuando la muestra poblacional de los adultos se distribuy&#243; por grupos de edad y g&#233;neros, ocurri&#243; una p&#233;rdida de poder debido al peque&#241;o tama&#241;o de los grupos, especialmente en el grupo de edad arriba de los 80 a&#241;os, y, consecuentemente, ocurri&#243; una p&#233;rdida en la capacidad de generalizaci&#243;n de los datos encontrados. </p>
      <p>
        <bold>Conclusi&#243;n</bold>
      </p>
      <p>La prevalencia de s&#237;ndrome metab&#243;lico entre los adultos mayores representativos de la comunidad fue mayor con el criterio de la IDF, seguido por los criterios del NCEP ATP III revisado y del NCEP ATP III. Adem&#225;s de eso, la prevalencia del s&#237;ndrome metab&#243;lico fue siempre mayor entre las mujeres en la muestra poblacional estudiada, independientemente del criterio utilizado. </p>
      <p>Potencial Conflicto de Intereses</p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>Fuentes de Financiaci&#243;n</p>
      <p>El presente estudio no tuvo fuentes de financiaci&#243;n externas.</p>
      <p>Vinculaci&#243;n Acad&#233;mica</p>
      <p>Este art&#237;culo forma parte de tesis de Maestr&#237;a de J&#250;lio C&#233;sar Rigo, por la Universidad Cat&#243;lica del R&#237;o Grande del Sur.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
